<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Alpha‐lipoic acid for diabetic peripheral neuropathy - Baicus, C - 2024 | Cochrane Library</title> <meta content="Alpha‐lipoic acid for diabetic peripheral neuropathy - Baicus, C - 2024 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012967.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Alpha‐lipoic acid for diabetic peripheral neuropathy - Baicus, C - 2024 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012967.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012967.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Alpha‐lipoic acid for diabetic peripheral neuropathy" name="citation_title"/> <meta content="Cristian Baicus" name="citation_author"/> <meta content="Carol Davila University of Medicine and Pharmacy" name="citation_author_institution"/> <meta content="cristian.baicus@umfcd.ro" name="citation_author_email"/> <meta content="Adrian Purcarea" name="citation_author"/> <meta content="Erik von Elm" name="citation_author"/> <meta content="University of Lausanne" name="citation_author_institution"/> <meta content="Caterina Delcea" name="citation_author"/> <meta content="Carol Davila University of Medicine and Pharmacy" name="citation_author_institution"/> <meta content="Florentina L Furtunescu" name="citation_author"/> <meta content="Carol Davila University of Medicine and Pharmacy" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD012967.pub2" name="citation_doi"/> <meta content="2024" name="citation_date"/> <meta content="2024/01/11" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012967.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012967.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012967.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Diabetes Mellitus, Type 2 [complications, drug therapy]; *Diabetic Neuropathies [drug therapy]; Lower Extremity; MEDLINE; *Thioctic Acid [adverse effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012967.pub2&amp;doi=10.1002/14651858.CD012967.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012967.pub2&amp;doi=10.1002/14651858.CD012967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012967.pub2&amp;doi=10.1002/14651858.CD012967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012967.pub2&amp;doi=10.1002/14651858.CD012967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012967.pub2&amp;doi=10.1002/14651858.CD012967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012967.pub2&amp;doi=10.1002/14651858.CD012967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012967.pub2&amp;doi=10.1002/14651858.CD012967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012967.pub2&amp;doi=10.1002/14651858.CD012967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012967.pub2&amp;doi=10.1002/14651858.CD012967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012967.pub2&amp;doi=10.1002/14651858.CD012967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012967.pub2&amp;doi=10.1002/14651858.CD012967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012967.pub2&amp;doi=10.1002/14651858.CD012967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012967.pub2&amp;doi=10.1002/14651858.CD012967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012967.pub2&amp;doi=10.1002/14651858.CD012967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012967.pub2&amp;doi=10.1002/14651858.CD012967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012967.pub2&amp;doi=10.1002/14651858.CD012967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012967.pub2&amp;doi=10.1002/14651858.CD012967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012967.pub2&amp;doi=10.1002/14651858.CD012967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012967.pub2&amp;doi=10.1002/14651858.CD012967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012967.pub2&amp;doi=10.1002/14651858.CD012967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012967.pub2&amp;doi=10.1002/14651858.CD012967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012967.pub2&amp;doi=10.1002/14651858.CD012967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012967.pub2&amp;doi=10.1002/14651858.CD012967.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="ZDBB8PHY";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012967\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012967\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012967\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012967\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","pt","ko","ms","fr","hu","zh_HANT","th","fa","id","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012967.pub2",title:"Alpha\\u2010lipoic acid for diabetic peripheral neuropathy",firstPublishedDate:"Jan 11, 2024 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neuromuscular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZDBB8PHY&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012967.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012967.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012967.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012967.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012967.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012967.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hu&quot;,&quot;title&quot;:&quot;Összefoglalás közérthető nyelven&quot;},{&quot;language&quot;:&quot;id&quot;,&quot;title&quot;:&quot;Saripati tinjauan sistematik&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012967.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012967.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012967.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012967.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6030 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012967.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012967.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012967.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012967.pub2/full#CD012967-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012967.pub2/full#CD012967-sec-0071"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012967.pub2/full#CD012967-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012967.pub2/full#CD012967-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012967.pub2/full#CD012967-sec-0018"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012967.pub2/full#CD012967-sec-0019"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012967.pub2/full#CD012967-sec-0043"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012967.pub2/full#CD012967-sec-0065"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012967.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012967.pub2/appendices#CD012967-sec-0080"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012967.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012967.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012967.pub2/media/CDSR/CD012967/supinfo/CD012967-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012967.pub2/media/CDSR/CD012967/supinfo/CD012967-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012967.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012967.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012967.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012967.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012967.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012967.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2024 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Alpha‐lipoic acid for diabetic peripheral neuropathy</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012967.pub2/information#CD012967-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Cristian Baicus</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012967.pub2/information#CD012967-cr-0005">Adrian Purcarea</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012967.pub2/information#CD012967-cr-0006">Erik von Elm</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012967.pub2/information#CD012967-cr-0007">Caterina Delcea</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012967.pub2/information#CD012967-cr-0008">Florentina L Furtunescu</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/information/en#CD012967-sec-0089">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 11 January 2024 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012967.pub2">https://doi.org/10.1002/14651858.CD012967.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012967-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012967-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012967-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012967-abs-0018">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012967-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012967-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/pt#CD012967-abs-0005">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD012967-abs-0016">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012967-abs-0001" lang="en"> <section id="CD012967-sec-0001"> <h3 class="title" id="CD012967-sec-0001">Background</h3> <p>Diabetic peripheral neuropathy (DPN) is a frequent complication in people living with type 1 or type 2 diabetes. There is currently no effective treatment for DPN. Although alpha‐lipoic acid (ALA, also known as thioctic acid) is widely used, there is no consensus about its benefits and harms. </p> </section> <section id="CD012967-sec-0002"> <h3 class="title" id="CD012967-sec-0002">Objectives</h3> <p>To assess the effects of alpha‐lipoic acid as a disease‐modifying agent in people with diabetic peripheral neuropathy. </p> </section> <section id="CD012967-sec-0003"> <h3 class="title" id="CD012967-sec-0003">Search methods</h3> <p>On 11 September 2022, we searched the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE, Embase, and two clinical trials registers. We also searched the reference lists of the included studies and relevant review articles for additional references not identified by the electronic searches. </p> </section> <section id="CD012967-sec-0004"> <h3 class="title" id="CD012967-sec-0004">Selection criteria</h3> <p>We included randomised clinical trials (RCTs) that compared ALA with placebo in adults (aged 18 years or older) and that applied the study interventions for at least six months. There were no language restrictions. </p> </section> <section id="CD012967-sec-0005"> <h3 class="title" id="CD012967-sec-0005">Data collection and analysis</h3> <p>We used standard methods expected by Cochrane. The primary outcome was change in neuropathy symptoms expressed as changes in the Total Symptom Score (TSS) at six months after randomisation. Secondary outcomes were change in neuropathy symptoms at six to 12 months and at 12 to 24 months, change in impairment, change in any validated quality of life total score, complications of DPN, and adverse events. We assessed the certainty of the evidence using GRADE. </p> </section> <section id="CD012967-sec-0006"> <h3 class="title" id="CD012967-sec-0006">Main results</h3> <p>Our analysis incorporated three trials involving 816 participants. Two studies included people with type 1 or type 2 diabetes, while one study included only people with type 2 diabetes. The duration of treatment was between six months and 48 months. We judged all studies at high risk of overall bias due to attrition. </p> <p>ALA compared with placebo probably has little or no effect on neuropathy symptoms measured by TSS (lower score is better) after six months (mean difference (MD) −0.16 points, 95% confidence interval (CI) −0.83 to 0.51; 1 study, 330 participants; moderate‐certainty evidence). The CI of this effect estimate did not contain the minimal clinically important difference (MCID) of 0.97 points. ALA compared with placebo may have little or no effect on impairment measured by the Neuropathy Impairment Score‐Lower Limbs (NIS‐LL; lower score is better) after six months (MD −1.02 points, 95% CI −2.93 to 0.89; 1 study, 245 participants; low‐certainty evidence). However, we cannot rule out a significant benefit, because the lower limit of the CI surpassed the MCID of 2 points. There is probably little or no difference between ALA and placebo in terms of adverse events leading to cessation of treatment within six months (risk ratio (RR) 1.48, 95% CI 0.50 to 4.35; 3 studies, 1090 participants; moderate‐certainty evidence). </p> <p>No studies reported quality of life or complications associated with DPN.</p> </section> <section id="CD012967-sec-0007"> <h3 class="title" id="CD012967-sec-0007">Authors' conclusions</h3> <p>Our analysis suggests that ALA probably has little or no effect on neuropathy symptoms or adverse events at six months, and may have little or no effect on impairment at six months. All the studies were at high risk of attrition bias. Therefore, future RCTs should ensure complete follow‐up and transparent reporting of any participants missing from the analyses. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012967-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012967-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012967-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012967-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012967-abs-0019">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012967-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/hu#CD012967-abs-0012">Magyar</a> </li> <li class="section-language"> <a class="" href="full/id#CD012967-abs-0020">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012967-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012967-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD012967-abs-0021">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD012967-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012967-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD012967-abs-0017">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012967-abs-0015">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012967-abs-0002" lang="en"> <h3>Is alpha‐lipoic acid (a natural antioxidant) better than no treatment or dummy treatment for nerve damage in people with diabetes? </h3> <p><b>Key messages</b> </p> <p>• We found that alpha‐lipoic acid treatment compared with placebo (dummy treatment) probably has little or no effect on the symptoms of nerve damage and may have little or no effect on impairment after six months of treatment.<br/>• There is probably little or no difference between alpha‐lipoic acid and placebo in the occurrence of unwanted effects that cause people to stop using treatment.<br/>• We found no studies to help us answer whether alpha‐lipoic acid treatment can improve quality of life or complications of nerve damage (ulceration, amputation, or both) in people with diabetes. </p> <p><b>What is diabetic peripheral neuropathy?</b> </p> <p>People with diabetes have too much sugar in their blood because their pancreas cannot make any insulin (type 1 diabetes) or cannot make enough insulin (type 2 diabetes). Diabetes is one of the most common non‐communicable diseases (diseases not spread by infection), and it is becoming more common every year. People with both type 1 and type 2 diabetes develop complications. </p> <p>High blood sugar can decrease blood flow in the blood vessels that supply the nerves, resulting in nerve damage (diabetic peripheral neuropathy). The main symptom of this condition is pain. Other symptoms include tingling, a burning sensation, numbness, shooting or sharp aches, and even extreme sensitivity to clothes touching the skin. These symptoms are caused by direct nerve damage, which is different from typical pain caused by injury or tissue damage. For this reason, usual painkiller medicines do not alleviate pain caused by peripheral neuropathy. People with this condition can also experience weakness, loss of reflexes, or loss of sensation (together known as impairment), which can disrupt normal functions such as walking. </p> <p><b>How is diabetic peripheral neuropathy treated?</b> </p> <p>Medicines used to treat depression or epilepsy may improve symptoms of diabetic peripheral neuropathy. Some studies have suggested that alpha‐lipoic acid (an antioxidant made naturally in the body) may help because of its presumed anti‐inflammatory effects. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to find out if alpha‐lipoic acid was better than no treatment or placebo (dummy treatment) for improving symptoms of diabetic peripheral neuropathy, impairment, quality of life, and complications of diabetic peripheral neuropathy (ulceration, amputation, or both) in people with type 1 or type 2 diabetes. We also wanted to know if alpha‐lipoic acid had any unwanted effects. </p> <p><b>What did we do?</b> </p> <p>We searched for studies that investigated alpha‐lipoic acid treatment compared to no treatment or placebo for at least six months. We analysed and summarised the results of the trials and rated our confidence in the findings. </p> <p><b>What did we find?</b> </p> <p>We found three studies that analysed 816 adults with type 1 and type 2 diabetes. The participants received either alpha‐lipoic acid or placebo. The dose of alpha‐lipoic acid ranged from 600 mg/day to 1800 mg/day. </p> <p>Alpha‐lipoic acid compared to placebo probably has little or no effect on symptoms of diabetic peripheral neuropathy and may have little or no effect on impairment after six months of treatment. There is probably little or no difference between alpha‐lipoic acid and placebo in terms of unwanted effects that cause people to stop treatment. </p> <p>No studies measured the effect of alpha‐lipoic acid treatment on quality of life or complications of peripheral neuropathy. </p> <p>Until alpha‐lipoic acid is proven effective, there is no rationale for comparing it with active treatments. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>We are moderately confident in the evidence on symptoms and unwanted effects because in all three studies, the investigators lost contact with many participants before the end of treatment (loss to follow‐up). We have little confidence in the evidence on impairment, because of loss to follow‐up and because the result was very imprecise. </p> <p><b>How up‐to‐date is this evidence?</b> </p> <p>The evidence is current to 11 September 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012967-sec-0071" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012967-sec-0071"></div> <h3 class="title" id="CD012967-sec-0072">Implications for practice</h3> <section id="CD012967-sec-0072"> <section id="CD012967-sec-0073"> <h5 class="title">For patients</h5> <p>Treatment with alpha‐lipoic acid (ALA) probably has little or no effect on neuropathy symptoms after six months of therapy or on functional impairment after 24 months of therapy in people with diabetic peripheral neuropathy (DPN). ALA may have little or no effect on functional impairment after six months of therapy. ALA probably has no adverse effects that would lead to treatment cessation within six months. </p> <p>We found no studies assessing the impact of ALA treatment on quality of life or on the complications of DPN (foot ulceration, amputation, or both). </p> </section> <section id="CD012967-sec-0074"> <h5 class="title">For clinicians</h5> <p>There was moderate‐certainty evidence from one study that ALA treatment has little or no effect on DPN symptoms (Total Symptom Score; TSS) after six months of treatment, and moderate‐certainty evidence from another study that ALA treatment has little or no effect on DPN symptoms (TSS) after 24 months of treatment. </p> <p>There was low‐certainty evidence from one study that ALA treatment compared with placebo has little or no effect on impairment assessed by the Neuropathy Impairment Score‐Lower Limbs (NIS‐LL) after six months of treatment. There was moderate‐certainty evidence from two studies using different scales (NIS‐LL and Neuropathy Disability Score) that ALA treatment compared with placebo has little or no effect on impairment after 24 months of treatment. </p> <p>There were no data on the impact of ALA treatment on quality of life or DPN complications (foot ulceration, amputation, or both). </p> <p>There was moderate‐certainty evidence from three studies of little or no difference between ALA and placebo in terms of adverse events that would lead to cessation of treatment after six months. </p> </section> <section id="CD012967-sec-0075"> <h5 class="title">For policymakers and funders</h5> <p>There is moderate‐certainty data that ALA has little or no effect on symptoms of DPN.</p> <p>There is low‐ and moderate‐certainty data that ALA has little or no effect on impairment.</p> <p>There are no data on the effect of ALA on quality of life or DPN complications.</p> </section> </section> <h3 class="title" id="CD012967-sec-0076">Implications for research</h3> <section id="CD012967-sec-0076"> <p>We found only three randomised clinical trials assessing the efficacy of long‐term treatment (more than six months) of DPN with ALA compared to placebo. All were at high risk of attrition bias; therefore, future RCTs should ensure complete follow‐up and transparent reporting of any participants missing in the analyses. Studies should also measure symptoms, impairment, and quality of life using validated scales. Other important outcomes are complications of DPN (foot ulceration, amputation, or both) and adverse effects. </p> <p>Intensive glycaemic control is considered the primary approach for preventing DPN, and haemoglobin A1C (HbA1C) is widely recognised as the most reliable biomarker for assessing glycaemic control. It is important to note that ALA is not expected to directly affect HbA1C levels, and only limited evidence suggests its potential as an insulin sensitiser. In the included studies, no significant variation was observed in HbA1C levels between baseline and end of follow‐up in the intervention or control groups. However, future studies may assess the role of glycaemic control as a modifier of the potential effect of ALA. </p> <p>Until ALA is proven effective, there is no rationale for comparing it with active treatments. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012967-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012967-sec-0008"></div> <div class="table" id="CD012967-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Alpha‐lipoic acid compared to placebo for diabetic peripheral neuropathy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Alpha‐lipoic acid compared to placebo for diabetic peripheral neuropathy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with DPN<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> ALA<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with ALA</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in neuropathy symptoms</b><br/>Assessed with: TSS (0 to 14.64, lower is better)<br/>Follow‐up: 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>330<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change was 3.78 points lower</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.16 points lower</b><br/>(0.83 lower to 0.51 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA compared to placebo probably has little or no effect on neuropathy symptoms after 6 months. The 95% CI did not contain the MCID of 0.97 points (<a href="./references#CD012967-bbs2-0011" title="Bastyr EJ 3rd, PriceKL , BrilV , MBBQ Study Group. Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy. Clinical Therapeutics2005;27(8):1278-94.">Bastyr 2005</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in impairment</b><br/>Assessed with: NIS‐LL (0 to 88, lower is better)<br/>Follow‐up: 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>245<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change was 3.37 points lower</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 1.02 points lower</b><br/>(2.93 lower to 0.89 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA compared to placebo may have little or no effect on impairment after 6 months. However, the lower 95% CI limit surpasses the MCID of 2 points (<a href="./references#CD012967-bbs2-0024" title="DyckPJ , KratzKM , LehmanKA , KarnesJL , Melton LJ 3rd, O'BrienPC , et al. The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests. Neurology1991;41(6):799-807.">Dyck 1991</a>; <a href="./references#CD012967-bbs2-0048" title="Peripheral Nerve Society. Diabetic polyneuropathy clinical trials: consensus in controlled report of the peripheral nerve society. Annals of Neurology1995;38(3):478-82.">Peripheral Nerve Society 1995</a>), so we cannot rule out a beneficial effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in any validated quality of life score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Complications of DPN</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events leading to cessation of treatment</b><br/>Follow‐up: 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1090<br/>(3 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.48</b><br/>(0.50 to 4.35) </p> </td> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There is probably little or no difference between alpha‐lipoic acid and placebo probably results in little or no difference in adverse events at 6 months. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 more per 1000<br/>(1 fewer to 7 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ALA:</b> alpha‐lipoic acid; <b>CI:</b> confidence interval; <b>DPN:</b> diabetic peripheral neuropathy; <b>MCID</b> : minimal clinically important difference; <b>MD</b> : mean difference; <b>NIS‐LL:</b> Neuropathy Impairment Score‐Lower Limbs <b>RCT</b> : randomised clinical trial; <b>RR:</b> risk ratio; <b>TSS:</b> Total Symptom Score. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once for risk of bias (attrition bias).<br/><sup>b</sup>Downgraded once for risk of bias (attrition bias) and once for imprecision (95% CI contains the MCID).<br/><sup>c</sup>Downgraded once for risk of bias (attrition bias). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012967-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012967-sec-0009"></div> <section id="CD012967-sec-0010"> <h3 class="title" id="CD012967-sec-0010">Description of the condition</h3> <section id="CD012967-sec-0011"> <h4 class="title">Epidemiology of diabetes mellitus and diabetic polyneuropathy</h4> <p>Diabetes mellitus is one of the most common non‐communicable diseases and a leading public health concern. Chronic hyperglycaemia arises from two main conditions: insufficient insulin production, known as type 1 diabetes (previously insulin‐dependent diabetes); and insulin resistance, known as type 2 diabetes (previously non‐insulin dependent diabetes; <a href="./references#CD012967-bbs2-0067" title="World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus (WHO/NCD/NCS/99.2). Geneva: World Health Organization. apps.who.int/iris/bitstream/10665/66040/1/WHO_NCD_NCS_99.2.pdf1999.">WHO 1999</a>). As reported in the 9th edition of the International Diabetes Federation Diabetes Atlas, nearly half a billion people worldwide were living with diabetes in 2019. Projections estimate a 25% increase in prevalence by 2030 and a 51% increase by 2045 (<a href="./references#CD012967-bbs2-0057" title="SaeediP , PetersohnI , SalpeaP , MalandaB , KarurangaS , UnwinN , et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Research and Clinical Practice2019;157:107843. [DOI: 10.1016/j.diabres.2019.107843]">Saeedi 2019</a>). People with both types of diabetes can develop multisystem chronic complications, with diabetic neuropathies being the most frequent (<a href="./references#CD012967-bbs2-0037" title="International Diabetes Federation. IDF Diabetes Atlas. 10th edition. Brussels: International Diabetes Federation, 2021.">IDF 2021</a>; <a href="./references#CD012967-bbs2-0068" title="World Health Organization. Global Report on Diabetes. 2016. www.who.int/diabetes/global-report/en/ (accessed 22 May 2017).">WHO 2016</a>). These are classified clinically as either diffuse or atypical (e.g. mononeuropathies, radiculopathies, or polyradiculopathies; <a href="./references#CD012967-bbs2-0051" title="Pop-BusuiR , BoultonAJ , FeldmanEL , BrilV , FreemanR , MalikRA , et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care 2017;40(1):136-54. [DOI: 10.2337/dc16-2042]">Pop‐Busui 2017</a>). Both the sensorimotor and autonomic nervous systems can be affected by diffuse disease. Sensorimotor polyneuropathy disease can involve either large or small nerve fibres, is usually predominantly sensory, and is often painful (<a href="./references#CD012967-bbs2-0025" title="EdwardsJL , VincentAM , ChengHT , FeldmanEL . Diabetic neuropathy: mechanisms to management. Pharmacology &amp; Therapeutics2008;120(1):1-34. [DOI: 10.1016/j.pharmthera.2008.05.005]">Edwards 2008</a>). </p> <p>Across the spectrum of nervous system involvement, distal symmetric polyneuropathy (referred to as diabetic peripheral neuropathy (DPN) in this review) is the most common form, accounting for up to 75% of diabetic neuropathies (<a href="./references#CD012967-bbs2-0010" title="BansalV , KalitaJ , MisraUK . Diabetic neuropathy. Postgraduate Medical Journal 2006 Feb;82(964):95-100. [DOI: 10.1136/pgmj.2005.036137]">Bansal 2006</a>). The estimated prevalence in the diabetic population ranges from 8% to 54% (<a href="./references#CD012967-bbs2-0030" title="FeldmanEL , CallaghanBC , Pop-BusuiR , ZochodneDW , WrightDE , BennettDL , et al. Diabetic neuropathy. Nature Reviews Disease Primers2019;5(1):41. [DOI: 10.1038/s41572-019-0092-1]">Feldman 2019</a>), and the four‐year cumulative incidence ranges from 66% to 74%, increasing with age and disease duration (<a href="./references#CD012967-bbs2-0050" title="Pop-BusuiR , LuJ , Mori BrooksM , AlbertS , AlthouseAD , EscobedoJ , et al. Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort. Diabetes Care2013;36(10):32-15. [DOI: 10.2337/dc13-0012]">Pop‐Busui 2013</a>). </p> <p>DPN is a major cause of morbidity and is the primary cause of non‐traumatic amputations. It is also associated with considerable physical disability, altered quality of life, and increased mortality (<a href="./references#CD012967-bbs2-0013" title="BoultonAJ , VinikAI , ArezzoJC , BrilV , FeldmanEL , FreemanR , et al. American Diabetes Association. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care2005;28(4):956-62. [PMID: 15793206]">Boulton 2005</a>; <a href="./references#CD012967-bbs2-0062" title="TesfayeS , VileikyteL , RaymanG , SindrupSH , PerkinsBA , BaconjaM , et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes/Metabolism Research and Reviews2011;27(7):629-38. [DOI: 10.1007/BF00400697]">Tesfaye 2011</a>). </p> <p>Regular screening for DPN signs and symptoms is crucial to identify the disease in its earliest stages and intervene promptly, preventing the development of complications (<a href="./references#CD012967-bbs2-0051" title="Pop-BusuiR , BoultonAJ , FeldmanEL , BrilV , FreemanR , MalikRA , et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care 2017;40(1):136-54. [DOI: 10.2337/dc16-2042]">Pop‐Busui 2017</a>). </p> </section> <section id="CD012967-sec-0012"> <h4 class="title">Clinical manifestations of diabetic polyneuropathy</h4> <p>From a clinical perspective, DPN is defined as "the presence of symptoms and/or signs of peripheral nerve dysfunction in people with diabetes after the exclusion of other causes" (<a href="./references#CD012967-bbs2-0010" title="BansalV , KalitaJ , MisraUK . Diabetic neuropathy. Postgraduate Medical Journal 2006 Feb;82(964):95-100. [DOI: 10.1136/pgmj.2005.036137]">Bansal 2006</a>; <a href="./references#CD012967-bbs2-0012" title="BoultonAJ , GriesFA , JervellJA . Guidelines for the diagnosis and outpatient management diabetic peripheral neuropathy. Diabetic Medicine1998;15(6):508-14.">Boulton 1998</a>). DPN may be asymptomatic and insidious at onset. It may be sensory or motor and may affect small or large fibres, or both (<a href="./references#CD012967-bbs2-0010" title="BansalV , KalitaJ , MisraUK . Diabetic neuropathy. Postgraduate Medical Journal 2006 Feb;82(964):95-100. [DOI: 10.1136/pgmj.2005.036137]">Bansal 2006</a>). </p> <p>The most common symptom of DPN is neuropathic pain caused by involvement of small fibres, which occurs in up to 50% of people with DPN and is the most frequent reason for seeking medical care (<a href="./references#CD012967-bbs2-0014" title="BredfeldtC , AltschulerA , AdamsAS , PortsJ , BaylissE . Patient reported outcomes for diabetic peripheral neuropathy. Journal of Diabetes and Its Complications2015;29(8):1112-8.">Bredfeldt 2015</a>; <a href="./references#CD012967-bbs2-0062" title="TesfayeS , VileikyteL , RaymanG , SindrupSH , PerkinsBA , BaconjaM , et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes/Metabolism Research and Reviews2011;27(7):629-38. [DOI: 10.1007/BF00400697]">Tesfaye 2011</a>). Painful symptoms are varied and include tingling, burning sensations, paraesthesia, shooting or lancinating pains, aching, and allodynia, defined as pain elicited by normally innocuous stimuli, such as contact with clothing (<a href="./references#CD012967-bbs2-0062" title="TesfayeS , VileikyteL , RaymanG , SindrupSH , PerkinsBA , BaconjaM , et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes/Metabolism Research and Reviews2011;27(7):629-38. [DOI: 10.1007/BF00400697]">Tesfaye 2011</a>). Involvement of large fibres manifests as painless paraesthesia with vibration impairment, touch and pressure sensations, and loss of ankle reflex, with the possibility of sensory ataxia in advanced stages (<a href="./references#CD012967-bbs2-0010" title="BansalV , KalitaJ , MisraUK . Diabetic neuropathy. Postgraduate Medical Journal 2006 Feb;82(964):95-100. [DOI: 10.1136/pgmj.2005.036137]">Bansal 2006</a>). </p> <p>DPN complications are also a major threat to the general well‐being and quality of life of people with diabetes. Sensory loss, along with retinopathy and vestibular dysfunction, increases the risk of falls two‐ to three‐fold in people with versus people without DPN (<a href="./references#CD012967-bbs2-0007" title="AgrawalY , CareyJP , Della SantinaCC , SchubertMC , MinorLB . Diabetes, vestibular dysfunction, and falls: analyses from the National Health and Nutrition Examination Survey. Otology &amp; Neurotology2010;31(9):1445-50. [DOI: 10.1097/MAO.0b013e3181f2f035.]">Agrawal 2010</a>). People with DPN are also seven times more likely to develop foot ulcerations (<a href="./references#CD012967-bbs2-0009" title='AminN , DoupisJ . Diabetic foot disease: from the evaluation of the "foot at risk" to the novel diabetic ulcer treatment modalities. World Journal of Diabetes2016;7(7):153-64. [DOI: 10.4239/wjd.v7.i7.153.]'>Amin 2016</a>). This further predisposed them to active or passive soft tissue infection, which can progress to bone infection and subsequent lower extremity amputation (<a href="./references#CD012967-bbs2-0039" title="KimPJ , SteinbergJS . Complications of the diabetic foot. Endocrinology and Metabolism Clinics of North America2013;42(4):833-47. [DOI: 10.1016/j.ecl.2013.08.002]">Kim 2013</a>). DPN, peripheral vascular disease, and soft tissue and bone deformity are serious complications that make diabetes the leading cause of lower extremity amputation (<a href="./references#CD012967-bbs2-0016" title="CallaghanBC , ChengHT , StablesCL , SmithAL , FeldmanEL . Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurology2012;11(6):521-34. [DOI: 10.1016/S1474-4422(12)70065-0]">Callaghan 2012a</a>). </p> <p>DPN symptoms are usually assessed using patient‐reported outcome measures that quantify discomfort, sleep disturbances, and quality of life (<a href="./references#CD012967-bbs2-0014" title="BredfeldtC , AltschulerA , AdamsAS , PortsJ , BaylissE . Patient reported outcomes for diabetic peripheral neuropathy. Journal of Diabetes and Its Complications2015;29(8):1112-8.">Bredfeldt 2015</a>). </p> </section> <section id="CD012967-sec-0013"> <h4 class="title">Pathophysiology of diabetic polyneuropathy</h4> <p>DPN primarily involves sensory and autonomic axons, and to a lesser extent, motor axons (<a href="./references#CD012967-bbs2-0030" title="FeldmanEL , CallaghanBC , Pop-BusuiR , ZochodneDW , WrightDE , BennettDL , et al. Diabetic neuropathy. Nature Reviews Disease Primers2019;5(1):41. [DOI: 10.1038/s41572-019-0092-1]">Feldman 2019</a>). Substantial experimental data support the idea that DPN affects the entire neuron, from the perikaryon to the distal terminals (<a href="./references#CD012967-bbs2-0030" title="FeldmanEL , CallaghanBC , Pop-BusuiR , ZochodneDW , WrightDE , BennettDL , et al. Diabetic neuropathy. Nature Reviews Disease Primers2019;5(1):41. [DOI: 10.1038/s41572-019-0092-1]">Feldman 2019</a>). However, the pathophysiology of DPN is not fully understood and is likely multifactorial, encompassing genetic, environmental, behavioural, metabolic, neurotrophic, and vascular factors (<a href="./references#CD012967-bbs2-0019" title="ChenW , ZhangY , LiX , YangG , LiuJP . Chinese herbal medicine for diabetic peripheral neuropathy. Cochrane Database of Systematic Reviews2013, Issue 10. Art. No: CD007796. [DOI: 10.1002/14651858.CD007796.pub3]">Chen 2013</a>; <a href="./references#CD012967-bbs2-0069" title="XuQ , PanJ , YuJ , LiuX , LiuL , ZuoX , et al. Meta-analysis of methylcobalamin alone and in combination with lipoic acid in patients with diabetic peripheral neuropathy. Diabetes Research and Clinical Practice2013;101(2):99-105. [DOI: 10.1016/j.diabres.2013.03.033]">Xu 2013</a>). Oxidative stress, whether it arises from an overproduction of free radicals, a deficiency in antioxidant protection, or both, is believed to play a crucial role in the disease's pathogenesis (<a href="./references#CD012967-bbs2-0041" title="LowPA , NickanderKK , TritschlerHJ . The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes1997;46(Suppl 2):S38-42.">Low 1997</a>). While good glycaemic control can lower the risk of DPN development, it is not always possible to achieve and is typically insufficient to halt the progression of DPN (<a href="./references#CD012967-bbs2-0019" title="ChenW , ZhangY , LiX , YangG , LiuJP . Chinese herbal medicine for diabetic peripheral neuropathy. Cochrane Database of Systematic Reviews2013, Issue 10. Art. No: CD007796. [DOI: 10.1002/14651858.CD007796.pub3]">Chen 2013</a>; <a href="./references#CD012967-bbs2-0021" title="Diabetes Control and Complications Trial Research Group, NathanDM , GenuthS , LachinJ , ClearyP , CroffordO , et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine1993;329(14):977-86.">DCCT 1993</a>; <a href="./references#CD012967-bbs2-0023" title="DuckworthW , AbrairaC , MoritzT , RedaD , EmanueleN , ReavenPD , et al. Glucose control and vascular complications in veterans with type 2 diabetes. New England Journal of Medicine2009;360(2):129-39.">Duckworth 2009</a>; <a href="./references#CD012967-bbs2-0062" title="TesfayeS , VileikyteL , RaymanG , SindrupSH , PerkinsBA , BaconjaM , et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes/Metabolism Research and Reviews2011;27(7):629-38. [DOI: 10.1007/BF00400697]">Tesfaye 2011</a>). </p> <p>The pathophysiology of DPN can primarily be described as a neural dysfunction resulting from the interplay of reduced blood flow to nerves (due to hyperglycaemia) and increased oxidative stress, which induces local inflammatory reactions through reactive oxygen species (ROS; <a href="./references#CD012967-bbs2-0015" title="BrownleeM . The pathobiology of diabetic complications: a unifying mechanism. Diabetes2005;54(6):1615–25.">Brownlee 2005</a>). Prolonged hyperglycaemia can activate multiple pathways simultaneously, leading to: </p> <p> <ul id="CD012967-list-0001"> <li> <p>activation of polyol and protein kinase pathways, which leads to reduced nicotinamide adenine dinucleotide phosphate (NADPH) and subsequent depletion of glutathione and nitric oxide (<a href="./references#CD012967-bbs2-0028" title="FeldmanEL , StevensMJ , GreeneDA . Pathogenesis of diabetic neuropathy. Clinical Neuroscience1997;4(6):365-70.">Feldman 1997</a>; <a href="./references#CD012967-bbs2-0063" title="UeharaK , YamagishiS , OtsukiS , ChinS , YagihashiS . Effects of polyol pathway hyperactivity on protein kinase C activity, nociceptive peptide expression, and neuronal structure in dorsal root ganglia in diabetic mice. Diabetes2004;53(12):3239-47.">Uehara 2004</a>); </p> </li> <li> <p>stimulation of angiogenesis via the vascular endothelial growth factor pathway;</p> </li> <li> <p>induction of basement membrane thickening and endothelial proliferation (through transforming growth factor‐beta (TGF‐β) and nuclear factor‐kappa B (NFkB)), which cause altered capillary permeability and local hypoxia; </p> </li> <li> <p>activation of the hexosamine pathway and diversion of fructose‐6‐phosphate from the glycolytic pathway; and </p> </li> <li> <p>modification of gene expression for glucose transporters and glucokinase (<a href="./references#CD012967-bbs2-0040" title="Kolm-LittyV , SauerU , NerlichA , LehmannR , SchleicherED . High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. Journal of Clinical Investigation1998;101(1):160-9.">Kolm‐Litty 1998</a>). </p> </li> </ul> </p> <p>Generation of ROS and advanced glycosylation end‐products activate the same NFkB pathway, which increases oxidative stress and further depletes NADPH. Oxidative stress also induces the activation of poly(adenosine diphosphate‐ribose) polymerase, resulting in further nicotinamide adenine dinucleotide depletion, a positive feedback loop activation of the protein kinase pathway, and increased inflammation (<a href="./references#CD012967-bbs2-0065" title="VinikAI , MehrabyanA . Diabetic neuropathies. Medical Clinics of North America2004;88(4):947-99.">Vinik 2004</a>). All these pathways promote mitochondrial dysfunction, leading to apoptosis, axonal degeneration, and eventual axonal death. Local proinflammatory cytokines, induced by oxidative stress, promote macrophage recruitment, leading to subsequent glial failure, myelin breakdown, and impaired nerve regeneration (<a href="./references#CD012967-bbs2-0066" title="WangY , SchmeichelAM , IidaH , SchmelzerJD , LowPA . Enhanced inflammatory response via activation of NF-kappaB in acute experimental diabetic neuropathy subjected to ischemia reperfusion injury. Journal of the Neurological Sciences2006;247(1):47-52.">Wang 2006</a>). The overpowered antioxidant response allows the progression of a vast injury cascade initiated by ROS, which is accentuated by loss of adenosine triphosphate (ATP) production and neuronal dysfunction (<a href="./references#CD012967-bbs2-0031" title="FernyhoughP . Mitochondrial dysfunction in diabetic neuropathy: a series of unfortunate metabolic events. Current Diabetes Reports2015;15(11):89. [DOI: 10.1007/s11892-015-0671-9]">Fernyhough 2015</a>). Neuronal oxidative/nitrosative stress can also stimulate numerous downstream kinases and transcriptional factors, triggering a feed‐forward loop of injury (<a href="./references#CD012967-bbs2-0059" title="StavniichukR , ShevalyeH , LupachykS , ObrosovA , GrovesJT , ObrosovaIG , et al. Peroxynitrite and protein nitration in the pathogenesis of diabetic peripheral neuropathy. Diabetes Metabolism Research and Reviews2014;30(8):669-78. [DOI: 10.1002/dmrr.2549]">Stavniichuk 2014</a>) and the release of cytokines and chemokines (<a href="./references#CD012967-bbs2-0029" title=" FeldmanEL , BennettDL , NaveKA , JensenTS . New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain. Neuron2017;93(6):1296-313. [DOI: 10.1016/j.neuron.2017.02.005]">Feldman 2017</a>). Existing inflammation and immune responses are further stimulated, enhancing cellular oxidative/nitrosative stress, and leading to increased neuronal injury (<a href="./references#CD012967-bbs2-0064" title="VincentAM , CalabekB , RobertsL , FeldmanEL . Biology of diabetic neuropathy. Handbook of Clinical Neurology2013;115:591-606. [DOI: 10.1016/B978-0-444-52902-2.00034-5]">Vincent 2013</a>). These pathways primarily affect axons, while Schwann cells, exhibiting a much stronger innate antioxidant response, are at least partially protected against ROS damage (<a href="./references#CD012967-bbs2-0029" title=" FeldmanEL , BennettDL , NaveKA , JensenTS . New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain. Neuron2017;93(6):1296-313. [DOI: 10.1016/j.neuron.2017.02.005]">Feldman 2017</a>). </p> <p>The clinical consequences of this hyperglycaemia‐induced inflammatory and oxidative state include axonal dystrophy, decreased nerve conduction velocity, diminished neurovascular flow, and, ultimately, small and large fibre neuropathy (<a href="./references#CD012967-bbs2-0025" title="EdwardsJL , VincentAM , ChengHT , FeldmanEL . Diabetic neuropathy: mechanisms to management. Pharmacology &amp; Therapeutics2008;120(1):1-34. [DOI: 10.1016/j.pharmthera.2008.05.005]">Edwards 2008</a>; <a href="./references#CD012967-bbs2-0029" title=" FeldmanEL , BennettDL , NaveKA , JensenTS . New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain. Neuron2017;93(6):1296-313. [DOI: 10.1016/j.neuron.2017.02.005]">Feldman 2017</a>). </p> </section> <section id="CD012967-sec-0014"> <h4 class="title">Management of diabetic polyneuropathy</h4> <p>For the current management of DPN, there are three major treatment strategies: causal therapy (which includes lifestyle changes, intensive glucose and metabolic syndrome control, and overall cardiovascular risk reduction; <a href="./references#CD012967-bbs2-0022" title="DCCT Research Group. Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Annals of Neurology1995;38(6):869-80. [DOI: 10.1002/ana.410380607]">DCCT 1995</a>; <a href="./references#CD012967-bbs2-0027" title="ElafrosMA , AndersenH , BennettDL , SavelieffMG , ViswanathanV , CallaghanBC , et al. Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments. Lancet Neurology2022;21(10):922-36.">Elafros 2022</a>), pathogenesis‐oriented therapy, and symptomatic‐directed therapy (<a href="./references#CD012967-bbs2-0073" title="ZieglerD , PapanasN , SchnellO , NguyenBD , NguyenKT , KulkantrakornK , et al. Current concepts in the management of diabetic polyneuropathy. Journal of Diabetes Investigation2021;12(4):464-75. [DOI: 10.1111/jdi.13401]">Ziegler 2021a</a>). </p> <p>DPN guidelines issued by the American Diabetes Association (<a href="./references#CD012967-bbs2-0051" title="Pop-BusuiR , BoultonAJ , FeldmanEL , BrilV , FreemanR , MalikRA , et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care 2017;40(1):136-54. [DOI: 10.2337/dc16-2042]">Pop‐Busui 2017</a>), International Diabetes Foundation (<a href="./references#CD012967-bbs2-0036" title="IbrahimA . IDF Clinical Practice Recommendation on the Diabetic Foot: a guide for healthcare professionals. Diabetes Research and Clinical Practice2017;127:285-7. [DOI: 10.1016/j.diabres.2017.04.013]">Ibrahim 2017</a>), American Academy of Neurology (<a href="./references#CD012967-bbs2-0052" title="PriceR , SmithD , FranklinG , GronsethG , PignoneM , DavidWS , et al. Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary. Report of the AAN Guideline Subcommittee. Neurology2022;98(1):31-43. [DOI: 10.1212/WNL.0000000000013038]">Price 2022</a>), and German Diabetes Association (<a href="./references#CD012967-bbs2-0074" title="ZieglerD , KellerJ , MaierC , PannekJ . Diabetic neuropathy. Experimental and Clinical Endocrinology and Diabetes2021;129(S 01):S70-S81. [DOI: 10.1055/a-1284-6245]">Ziegler 2021b</a>) all recommend the use of tricyclic antidepressants (<a href="./references#CD012967-bbs2-0042" title="LunnMP , HughesRA , WiffenPJ . Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews2014, Issue 1. Art. No: CD007115. [DOI: 10.1002/14651858.CD007115.pub3]">Lunn 2014</a>; <a href="./references#CD012967-bbs2-0056" title="SaartoT , WiffenPJ . Antidepressants for neuropathic pain. Cochrane Database of Systematic Reviews2007, Issue 4. Art. No: CD005454. [DOI: 10.1002/14651858.CD005454.pub2]">Saarto 2007</a>), serotonin‐noradrenaline reuptake inhibitors (e.g. duloxetine or venlafaxine; <a href="./references#CD012967-bbs2-0008" title="AllenR , SharmaU , BarlasS . Clinical experience with desvenlafaxine in treatment of pain associated with diabetic peripheral neuropathy. Journal of Pain Research2014;7:339-51.">Allen 2014</a>), and anticonvulsants (e.g. gabapentin or pregabalin) as first‐ or second‐line treatments for painful DPN. Opioids and opioid‐like drugs (e.g. tramadol) are recommended as second‐ or third‐line treatments (<a href="./references#CD012967-bbs2-0058" title="SnedecorSJ , SudharshanL , CappelleriJC , SadoskyA , MehtaS , BottemanM . Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Practice2014;14(2):167-84.">Snedecor 2014</a>; <a href="./references#CD012967-bbs2-0062" title="TesfayeS , VileikyteL , RaymanG , SindrupSH , PerkinsBA , BaconjaM , et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes/Metabolism Research and Reviews2011;27(7):629-38. [DOI: 10.1007/BF00400697]">Tesfaye 2011</a>; <a href="./references#CD012967-bbs2-0072" title="ZieglerD . Treatment of diabetic polyneuropathy: update. 2006. Annals of the New York Academy of Sciences2006;1084:250-66.">Ziegler 2006</a>). </p> <p>Regarding pathogenesis‐oriented therapy, recommendations are less consistent across the guidelines, primarily due to a lack of sufficient high‐quality clinical data supporting the use of medications that target the inflammatory and oxidative stress mechanisms involved in the polyol, hexosamine, protein kinase C, and advanced glycation end product pathways (<a href="./references#CD012967-bbs2-0075" title="ZieglerD , TesfayeS , SpalloneV , GurievaI , Al KaabiJ , MankovskyB , et al. Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice: international expert consensus recommendations. Diabetes Research and Clinical Practice2022;186:109063. [DOI: 10.1016/j.diabres.2021.109063]">Ziegler 2022</a>). Two guidelines mention the use of alpha‐lipoic acid (ALA) to target the inflammatory pathways in DPN (<a href="./references#CD012967-bbs2-0008" title="AllenR , SharmaU , BarlasS . Clinical experience with desvenlafaxine in treatment of pain associated with diabetic peripheral neuropathy. Journal of Pain Research2014;7:339-51.">Allen 2014</a>; <a href="./references#CD012967-bbs2-0036" title="IbrahimA . IDF Clinical Practice Recommendation on the Diabetic Foot: a guide for healthcare professionals. Diabetes Research and Clinical Practice2017;127:285-7. [DOI: 10.1016/j.diabres.2017.04.013]">Ibrahim 2017</a>; <a href="./references#CD012967-bbs2-0074" title="ZieglerD , KellerJ , MaierC , PannekJ . Diabetic neuropathy. Experimental and Clinical Endocrinology and Diabetes2021;129(S 01):S70-S81. [DOI: 10.1055/a-1284-6245]">Ziegler 2021b</a>), while others do not (<a href="./references#CD012967-bbs2-0051" title="Pop-BusuiR , BoultonAJ , FeldmanEL , BrilV , FreemanR , MalikRA , et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care 2017;40(1):136-54. [DOI: 10.2337/dc16-2042]">Pop‐Busui 2017</a>; <a href="./references#CD012967-bbs2-0052" title="PriceR , SmithD , FranklinG , GronsethG , PignoneM , DavidWS , et al. Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary. Report of the AAN Guideline Subcommittee. Neurology2022;98(1):31-43. [DOI: 10.1212/WNL.0000000000013038]">Price 2022</a>). </p> </section> </section> <section id="CD012967-sec-0015"> <h3 class="title" id="CD012967-sec-0015">Description of the intervention</h3> <p>ALA, or thioctic acid, is a natural thiol often used as a dietary supplement. It is believed to have potent antioxidant properties and metal‐chelating functions, with capacity to regenerate endogenous antioxidants and stimulate glucose uptake (<a href="./references#CD012967-bbs2-0054" title="RochetteL , GhibuS , MuresanA , VergelyC . Alpha-lipoic acid: molecular mechanisms and therapeutic potential in diabetes. Canadian Journal of Physiology and Pharmacology2015;93(12):1021-7.">Rochette 2015</a>). The therapeutic use of ALA has been explored in various clinical scenarios, including cardiovascular diseases and diabetic complications such as DPN. Clinical trials have used different methods of administration (intravenous or oral), different doses (from 200 mg/day to 1800 mg/day), and different durations of treatment. Recommendations for maintenance therapy indicate a daily oral dose of 600 mg (<a href="./references#CD012967-bbs2-0075" title="ZieglerD , TesfayeS , SpalloneV , GurievaI , Al KaabiJ , MankovskyB , et al. Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice: international expert consensus recommendations. Diabetes Research and Clinical Practice2022;186:109063. [DOI: 10.1016/j.diabres.2021.109063]">Ziegler 2022</a>). </p> </section> <section id="CD012967-sec-0016"> <h3 class="title" id="CD012967-sec-0016">How the intervention might work</h3> <p>ALA, acting as a scavenger of ROS, possesses antioxidant properties that could potentially interrupt the oxidative stress‐inflammation pathways triggered in DPN. Thus, it could prove beneficial for both the prevention and treatment of DPN (<a href="./references#CD012967-bbs2-0054" title="RochetteL , GhibuS , MuresanA , VergelyC . Alpha-lipoic acid: molecular mechanisms and therapeutic potential in diabetes. Canadian Journal of Physiology and Pharmacology2015;93(12):1021-7.">Rochette 2015</a>). </p> <p>Early in‐vitro studies indicated that both ALA and its reduced form, dihydrolipoic acid (DHLA), are capable of scavenging ROS, including hydroxyl radicals, hypochlorous acid, and singlet oxygen (<a href="./references#CD012967-bbs2-0047" title="PackerL , WittEH , TritschlerHJ . Alpha-lipoic acid as a biological antioxidant. Free Radical Biology &amp; Medicine1995;19(2):227-50.">Packer 1995</a>). In vivo studies have also suggested that ALA can mitigate oxidative stress (<a href="./references#CD012967-bbs2-0044" title="MarangonK , DevarajS , TiroshO , PackerL , JialalI . Comparison of the effect of alpha-lipoic acid and alpha-tocopherol supplementation on measures of oxidative stress. Free Radical Biology &amp; Medicine1999;27(9-10):1114-21.">Marangon 1999</a>), contribute to the restoration of endogenous cellular antioxidant levels, decrease proinflammatory pathways (<a href="./references#CD012967-bbs2-0049" title="Petersen ShayK , MoreauRF , SmithEJ , HagenTM . Is alpha-lipoic acid a scavenger of reactive oxygen species in vivo? Evidence for its initiation of stress signaling pathways that promote endogenous antioxidant capacity. IUBMB Life2008;60(6):362-7. [DOI: 10.1002/iub.40]">Petersen 2008</a>), and potentially facilitate the regeneration of vitamins C and E (<a href="./references#CD012967-bbs2-0054" title="RochetteL , GhibuS , MuresanA , VergelyC . Alpha-lipoic acid: molecular mechanisms and therapeutic potential in diabetes. Canadian Journal of Physiology and Pharmacology2015;93(12):1021-7.">Rochette 2015</a>). </p> <p>The potential benefits of ALA for individuals with diabetes may extend beyond its antioxidant and anti‐inflammatory effects. It might also be instrumental in restoring glucose availability, enhancing insulin‐stimulated glucose transport, and increasing non‐oxidative and oxidative glucose metabolism in insulin‐resistant muscle cells (<a href="./references#CD012967-bbs2-0038" title="KhannaS , RoyS , PackerL , SenCK . Cytokine-induced glucose uptake in skeletal muscle: redox regulation and the role of alpha-lipoic acid. American Journal of Physiology1999;276(5 Pt 2):R1327-33.">Khanna 1999</a>; <a href="./references#CD012967-bbs2-0060" title="StreeperRS , HenriksenEJ , JacobS , HokamaJY , FogtDL , TritschlerHJ . Differential effects of lipoic acid stereoisomers on glucose metabolism in insulin-resistant skeletal muscle. American Journal of Physiology1997;273(1 Pt 1):E185-91.">Streeper 1997</a>). </p> </section> <section id="CD012967-sec-0017"> <h3 class="title" id="CD012967-sec-0017">Why it is important to do this review</h3> <p>As DPN is highly prevalent among people with diabetes and is associated with considerable morbidity and quality of life impairment, it is critical to prevent and treat this condition effectively and promptly. Although ALA is frequently used for DPN, there is currently no established universal consensus on its usage (<a href="./references#CD012967-bbs2-0075" title="ZieglerD , TesfayeS , SpalloneV , GurievaI , Al KaabiJ , MankovskyB , et al. Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice: international expert consensus recommendations. Diabetes Research and Clinical Practice2022;186:109063. [DOI: 10.1016/j.diabres.2021.109063]">Ziegler 2022</a>). Several published Cochrane reviews have assessed the effects of other treatments for DPN, such as aldose reductase inhibitors (<a href="./references#CD012967-bbs2-0018" title="ChalkC , BensteadTJ , MooreF . Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Cochrane Database of Systematic Reviews2007, Issue 4. Art. No: CD004572. [DOI: 10.1002/14651858.CD004572.pub2]">Chalk 2007</a>), Chinese herbal medicine (<a href="./references#CD012967-bbs2-0019" title="ChenW , ZhangY , LiX , YangG , LiuJP . Chinese herbal medicine for diabetic peripheral neuropathy. Cochrane Database of Systematic Reviews2013, Issue 10. Art. No: CD007796. [DOI: 10.1002/14651858.CD007796.pub3]">Chen 2013</a>), enhanced glucose control (<a href="./references#CD012967-bbs2-0017" title="BC, LittleAA , FeldmanEL , HughesRA . Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database of Systematic Reviews2012, Issue 6. Art. No: CD007543. [DOI: 10.1002/14651858.CD007543.pub2]">Callaghan 2012b</a>), and acetyl‐L‐carnitine (<a href="./references#CD012967-bbs2-0055" title="RolimLC , da SilvaEM , FlumignanRL , AbreuMM , DibSA . Acetyl-L-carnitine for the treatment of diabetic peripheral neuropathy. Cochrane Database of Systematic Reviews2019, Issue 6. Art. No: CD011265. [DOI: 10.1002/14651858.CD011265.pub2]">Rolim 2019</a>), but none have synthesised the evidence on ALA. If proven to be effective and safe, this drug could serve as a cost‐effective component in the long‐term management of DPN. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012967-sec-0018" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012967-sec-0018"></div> <p>To assess the effects of alpha‐lipoic acid as a disease‐modifying agent in people with diabetic peripheral neuropathy. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012967-sec-0019" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012967-sec-0019"></div> <section id="CD012967-sec-0020"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012967-sec-0021"> <h4 class="title">Types of studies</h4> <p>Randomised clinical trials (RCTs) and quasi‐RCTs that compared ALA with placebo or no treatment for a minimum duration of six months were eligible for inclusion in this review. There were no restrictions on publication status or language. </p> </section> <section id="CD012967-sec-0022"> <h4 class="title">Types of participants</h4> <p>We included studies involving adults (aged 18 years and older) with type 1 or type 2 diabetes mellitus and established DPN, regardless of participant sex or study setting. For this Cochrane review, we defined DPN as the "presence of symptoms and/or signs of peripheral nerve dysfunction in people with diabetes after excluding other causes" (<a href="./references#CD012967-bbs2-0012" title="BoultonAJ , GriesFA , JervellJA . Guidelines for the diagnosis and outpatient management diabetic peripheral neuropathy. Diabetic Medicine1998;15(6):508-14.">Boulton 1998</a>). DPN typically presents as a length‐dependent and symmetrical sensorimotor polyneuropathy (<a href="./references#CD012967-bbs2-0061" title="TesfayeS , BoultonAJ , DyckPJ , FreemanR , HorowitzM , KemplerP , et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care2010;33(10):2285-93.">Tesfaye 2010</a>). Asymptomatic neuropathy may be detected through abnormal nerve conduction tests, which provide an objective – albeit indirect – semi‐quantitative indication of the condition (<a href="./references#CD012967-bbs2-0061" title="TesfayeS , BoultonAJ , DyckPJ , FreemanR , HorowitzM , KemplerP , et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care2010;33(10):2285-93.">Tesfaye 2010</a>). Therefore, we included studies that used clinical or electrophysiological criteria (or both) for DPN diagnosis. </p> <p>Where studies included people younger and older than 18 years, and we were unable to obtain separate data for eligible participants, we included all participants, under the assumption that age would not influence the effect of ALA on DPN. </p> </section> <section id="CD012967-sec-0023"> <h4 class="title">Types of interventions</h4> <p>We included studies that administered ALA orally or intravenously, at any dose, for at least six months. Eligible comparators were placebo or no treatment. Studies that used co‐interventions were eligible if these interventions were equally applied across all groups. </p> </section> <section id="CD012967-sec-0024"> <h4 class="title">Types of outcome measures</h4> <p>We included studies that measured at least one of the following outcomes.</p> <section id="CD012967-sec-0025"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012967-list-0002"> <li> <p>Change in neuropathy symptoms, expressed as change in Total Symptom Score (TSS) or other validated symptom score at six months after randomisation. </p> </li> </ul> </p> </section> <section id="CD012967-sec-0026"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012967-list-0003"> <li> <p>Change in neuropathy symptoms, expressed as change in TSS or other validated symptom score at six to 12 months and at 12 to 24 months after randomisation. </p> </li> <li> <p>Change in impairment, as measured by validated metrics, at six months, six to 12 months, and 12 to 24 months after randomisation. Validated scores include the Medical Research Council (MRC) sum score, the Neuropathy Impairment Score (NIS), the Neuropathy Disability Score (NDS; an impairment score), and the Inflammatory Neuropathy Cause and Treatment (INCAT) Sensory Sum Score. </p> </li> <li> <p>Change in any validated quality of life total score at six months after randomisation</p> </li> <li> <p>Complications of DPN, including the number of participants with foot ulceration, amputation, or both at any stage after treatment </p> </li> <li> <p>Adverse events, categorised as follows</p> <ul id="CD012967-list-0004"> <li> <p>Any adverse event</p> </li> <li> <p>Adverse events leading to cessation of treatment</p> </li> <li> <p>Serious adverse events (i.e. any event that was life‐threatening or required prolonged hospitalisation) </p> </li> </ul> </li> </ul> </p> </section> </section> </section> <section id="CD012967-sec-0027"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012967-sec-0028"> <h4 class="title">Electronic searches</h4> <p>On 12 March 2018 and 11 September 2022, the Information Specialist of Cochrane Neuromuscular searched the following databases. </p> <p> <ul id="CD012967-list-0005"> <li> <p>Cochrane Neuromuscular Specialised Register via the Cochrane Register of Studies (CRS‐Web; <a href="./appendices#CD012967-sec-0081">Appendix 1</a>) </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) via CRS‐Web (Issue 1, 2018 for the first search, and Issue 3, 2022 for the updated search; <a href="./appendices#CD012967-sec-0082">Appendix 2</a>) </p> </li> <li> <p>MEDLINE via Ovid SP (1946 to 11 September 2022; <a href="./appendices#CD012967-sec-0083">Appendix 3</a>) </p> </li> <li> <p>Embase via Ovid SP (1974 to Week 37 2022; <a href="./appendices#CD012967-sec-0084">Appendix 4</a>) </p> </li> </ul> </p> <p>In March 2018 and September 2022, we also searched the following trial registries.</p> <p> <ul id="CD012967-list-0006"> <li> <p>US National Institutes of Health Ongoing Trials Registry ClinicalTrials.gov (<a href="http://ClinicalTrials.gov" target="_blank">clinicaltrials.gov</a>; <a href="./appendices#CD012967-sec-0085">Appendix 5</a>) </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP; <a href="https://trialsearch.who.int/" target="_blank">trialsearch.who.int</a>; <a href="./appendices#CD012967-sec-0086">Appendix 6</a>) </p> </li> </ul> </p> <p>There were no restrictions on language, date, or status of publication.</p> </section> <section id="CD012967-sec-0029"> <h4 class="title">Searching other resources</h4> <p>We conducted a thorough literature search by reviewing the reference lists of all included primary studies, as well as those of pertinent review articles. This was to ensure that we captured any additional references that might have been overlooked in the electronic searches. Given the comprehensiveness of our search strategy, we considered it unnecessary to reach out to individuals or organisations for further information. </p> </section> </section> <section id="CD012967-sec-0030"> <h3 class="title" id="CD012967-sec-0030">Data collection and analysis</h3> <section id="CD012967-sec-0031"> <h4 class="title">Selection of studies</h4> <p>Two review authors (CB and CD) independently reviewed the titles and abstracts of references identified through electronic searches (minus duplicates). We retrieved the full‐text articles of all potentially suitable studies, and another two review authors (AP and FF) independently assessed them using a standardised inclusion form. We resolved any disagreements regarding study relevance through discussion or by consulting a third review author (CB), if necessary. To avoid duplication of data, we consolidated multiple reports of the same study, ensuring that each unique study was the unit of interest. For transparency and thoroughness, we compiled a <a href="./references#CD012967-sec-0096" title="">Characteristics of excluded studies</a> table and created a PRISMA diagram (<a href="./references#CD012967-bbs2-0045" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Medicine2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097]">Moher 2009</a>). </p> </section> <section id="CD012967-sec-0032"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (AP and FF) independently extracted pertinent information concerning the study design and setting, population, interventions, outcomes, sources of funding, and any declared conflicts of interest of the trial investigators, using Covidence software (<a href="./references#CD012967-bbs2-0020" title="Covidence. Version accessed 1 May 2018. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.">Covidence</a>). The two review authors compared their findings and resolved any disagreements through discussion. As a testament to the consistency of our process, there was no need to involve a third review author. We contacted the authors of two included studies for additional clarifications, but we received no response. </p> </section> <section id="CD012967-sec-0033"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (AP and FF) independently evaluated the risk of bias of the included studies using the Cochrane risk of bias tool RoB 1, which covers the following domains (<a href="./references#CD012967-bbs2-0034" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In Higgins JP, Altman DG, Sterne JA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane 2017. Available from www.training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>). </p> <p> <ul id="CD012967-list-0007"> <li> <p>Random sequence generation</p> </li> <li> <p>Allocation concealment</p> </li> <li> <p>Blinding of participants and personnel</p> </li> <li> <p>Blinding of outcome assessors</p> </li> <li> <p>Incomplete outcome data</p> </li> <li> <p>Selective outcome reporting</p> </li> <li> <p>Other potential sources of bias</p> </li> </ul> </p> <p>For the last domain, we determined whether studies were conducted in a single centre or by a single investigator (<a href="./references#CD012967-bbs2-0043" title="MallikS , KallisC , LunnMPT , SmithAG . Gangliosides for the treatment of diabetic peripheral neuropathy. Cochrane Database of Systematic Reviews2014, Issue 3. Art. No: CD011028. [DOI: 10.1002/14651858.CD011028]">Mallik 2014</a>). We classified each study at low, high, or unclear risk of bias in each domain, and we populated a risk of bias table with our findings. We then provided a narrative description of the overall risk of bias for each study, based on whether any of the domains were deemed to have a high risk of bias. </p> </section> <section id="CD012967-sec-0034"> <h4 class="title">Measures of treatment effect</h4> <p>In our analysis, we calculated mean differences (MDs) with 95% confidence intervals (CIs) for homogeneous continuous outcome measures. Where studies used different scales to measure the same outcome, we calculated the standardised mean difference (SMD) with its 95% CI. For our dichotomous outcomes (adverse events), we used risk ratios (RRs) with 95% CIs. The scales used in our analysis all had the same directional interpretation: a lower score indicated less severity of symptoms or impairment. Thus, a negative change was indicative of an improvement in symptoms or impairment. </p> </section> <section id="CD012967-sec-0035"> <h4 class="title">Unit of analysis issues</h4> <p>All included studies were parallel‐group randomised trials.</p> <p>Two trials had three arms. We combined the sample sizes, means and standard deviations (SDs) across the two treatment arms of <a href="./references#CD012967-bbs2-0001" title="ReljanovicM , ReichelG , RettK , LobischM , SchuetteK , MollerW , et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Radical Research1999;31(3):171-9. [DOI: 10.1080/10715769900300721]">Reljanovic 1999</a> using the method described in section 6.5.2.10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012967-bbs2-0035" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook/archive/v6.3.">Higgins 2022</a>). We did not include one arm of <a href="./references#CD012967-bbs2-0002" title="ZieglerD , HanefeldM , RuhnauKJ , HascheH , LobischM , SchütteK , et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care1999;22(8):1296-301. [DOI: 10.2337/diacare.22.8.1296]">Ziegler 1999</a> in any meta‐analysis, because the participants received both intravenous ALA (for the first three weeks) and oral placebo (for the remaining six months), and we could not categorise the intervention as either treatment or placebo (due to the possible residual effect of the intravenous ALA). </p> <p>Had we included any studies that used no treatment as a control, we would have combined data from comparisons with placebo and no treatment groups in a single analysis. </p> </section> <section id="CD012967-sec-0036"> <h4 class="title">Dealing with missing data</h4> <p>We recorded dropout rates and included them in the risk of bias table. For continuous data, we performed an available case analysis. When interpreting the results of the review, we considered the potential impact of missing data (<a href="./references#CD012967-bbs2-0034" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In Higgins JP, Altman DG, Sterne JA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane 2017. Available from www.training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>). If SDs were missing, we calculated them from other measures such as P values, standard errors (SEs), and the limits of CIs. This procedure ensures that all available data are utilised effectively while also accounting for the potential bias introduced by missing data. </p> </section> <section id="CD012967-sec-0037"> <h4 class="title">Assessment of heterogeneity</h4> <p>First, we examined the trials to determine whether there were clinical reasons for heterogeneity. For assessing statistical heterogeneity across trials, we used the Chi<sup>2</sup> test and I<sup>2</sup> statistic. We evaluated heterogeneity in meta‐analyses with at least three studies. </p> </section> <section id="CD012967-sec-0038"> <h4 class="title">Assessment of reporting biases</h4> <p>Had we included at least 10 studies in any meta‐analysis, we would have evaluated publication bias by creating a funnel plot and performing the Egger test (<a href="./references#CD012967-bbs2-0026" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315(7109):629-34.">Egger 1997</a>). We searched for unpublished trials on trial registration databases. </p> </section> <section id="CD012967-sec-0039"> <h4 class="title">Data synthesis</h4> <p>We calculated the pooled treatment effects using the Cochrane software Review Manager 5 (<a href="./references#CD012967-bbs2-0053" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). We used a fixed‐effect model and performed a sensitivity analysis with the random‐effects model. </p> </section> <section id="CD012967-sec-0040"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We hypothesised that response to treatment might differ according to disease duration (long‐standing DPN less likely to improve), age (older participants less likely to improve), severity of the disease, types of diabetes (as their pathogenesis is different), and the presence of pain. We also expected that the route of administration may influence bioavailability and lead to different effects. </p> <p>However, we could not perform any subgroup analyses because the sample sizes were small, and the information from the included studies was insufficient. </p> </section> <section id="CD012967-sec-0041"> <h4 class="title">Sensitivity analysis</h4> <p>We did not perform any sensitivity analysis according to risk of bias because all the studies were at high risk of bias. We did not perform a sensitivity analysis with the random‐effects model because either the outcomes included only one study, or there was no heterogeneity. </p> </section> <section id="CD012967-sec-0042"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We assessed the certainty of the evidence using the five GRADE considerations (risk of bias, inconsistency, indirectness, imprecision, and publication bias) as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012967-bbs2-0035" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook/archive/v6.3.">Higgins 2022</a>). We downgraded the certainty rating by one or two levels for limitations related to each consideration, up to a maximum of three levels for all considerations. Three review authors independently assessed the certainty of the evidence and resolved differences in opinion through discussion. </p> <p>We included the following outcome measures in the summary of findings table.</p> <p> <ul id="CD012967-list-0008"> <li> <p>Change in neuropathy symptoms at six months after randomisation</p> </li> <li> <p>Change in impairment at six months after randomisation</p> </li> <li> <p>Change in any validated quality of life total score at six months after randomisation</p> </li> <li> <p>Complications of DPN</p> </li> <li> <p>Adverse events leading to cessation of treatment</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012967-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012967-sec-0043"></div> <section id="CD012967-sec-0044"> <h3 class="title">Description of studies</h3> <section id="CD012967-sec-0045"> <h4 class="title">Results of the search</h4> <p>Our searches identified 517 references, of which 230 were duplicates. Of the remaining 287 references, we excluded 282 based on their titles and abstracts (not RCTs or quasi‐RCTS, treatment duration shorter than six months, or control intervention other than placebo or no treatment). We assessed five full‐text articles, excluding one (<a href="./references#CD012967-bbs2-0004" title="MedvedevaLA , GnezdilovAV , Zagorul'koOI , SyroveginAV , SamoilovaNV , Slashchuk IuI. Neurometabolic therapy of diabetic neuropathy. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov [i] Vserossiiskoe obshchestvo psikhiatrov2006;203:71-3. ">Medvedeva 2006</a>). For one of the four remaining studies, we found some discrepancies between the content of a conference abstract and the later full‐text article (<a href="./references#CD012967-bbs2-0005" title="El-NahasMR , El KannishyG , AbdelhafezH , TaherI , El SehrawyA . Oral alpha-lipoic acid adjunctive treatment for symptomatic diabetic peripheral neuropathy: a prospective, double blind, placebo controlled study. 53rd Annual Meeting of the European Association for the Study of Diabetes, 2017, Lisbon. www.easd.org/media-centre/home.html#!resources/oral-alpha-lipoic-acid-adjunctive-treatment-for-symptomatic-diabetic-peripheral-neuropathy-a-prospective-double-blind-placebo-controlled-study (accessed 20 December 2023). El-NahasMR , ElkannishyG , AbdelhafezH , ElkhamisyET , El-SehrawyAA . Oral alpha lipoic acid treatment for symptomatic diabetic peripheral neuropathy: a randomized double-blinded placebo-controlled study. Endocrine, Metabolic and Immune Disorders Drug Targets2020;20(9):1531-4. [DOI: 10.2174/1871530320666200506081407]">El Nahas 2020</a>). We were unable to obtain the trial data from the trialists, so we decided to list this study as awaiting classification. We included three studies in our qualitative and quantitative synthesis (<a href="./references#CD012967-bbs2-0001" title="ReljanovicM , ReichelG , RettK , LobischM , SchuetteK , MollerW , et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Radical Research1999;31(3):171-9. [DOI: 10.1080/10715769900300721]">Reljanovic 1999</a>; <a href="./references#CD012967-bbs2-0002" title="ZieglerD , HanefeldM , RuhnauKJ , HascheH , LobischM , SchütteK , et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care1999;22(8):1296-301. [DOI: 10.2337/diacare.22.8.1296]">Ziegler 1999</a>; <a href="./references#CD012967-bbs2-0003" title="ZieglerD , LowPA , LitchyWJ , BoultonAJ , VinikAI , FreemanR , et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care2011;34(9):2054-60. [DOI: 10.2337/dc11-0503]">Ziegler 2011</a>). </p> <p><a href="#CD012967-fig-0001">Figure 1</a> illustrates the study selection process in a PRISMA diagram. </p> <div class="figure" id="CD012967-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012967-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012967.pub2/media/CDSR/CD012967/image_n/nCD012967-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012967-sec-0046"> <h4 class="title">Included studies</h4> <p>All three included studies were placebo‐controlled, parallel‐group RCTs. Two studies had three arms (<a href="./references#CD012967-bbs2-0001" title="ReljanovicM , ReichelG , RettK , LobischM , SchuetteK , MollerW , et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Radical Research1999;31(3):171-9. [DOI: 10.1080/10715769900300721]">Reljanovic 1999</a>; <a href="./references#CD012967-bbs2-0002" title="ZieglerD , HanefeldM , RuhnauKJ , HascheH , LobischM , SchütteK , et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care1999;22(8):1296-301. [DOI: 10.2337/diacare.22.8.1296]">Ziegler 1999</a>), and one study had two arms (<a href="./references#CD012967-bbs2-0003" title="ZieglerD , LowPA , LitchyWJ , BoultonAJ , VinikAI , FreemanR , et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care2011;34(9):2054-60. [DOI: 10.2337/dc11-0503]">Ziegler 2011</a>). </p> <p>Two studies had two phases of treatment (<a href="./references#CD012967-bbs2-0001" title="ReljanovicM , ReichelG , RettK , LobischM , SchuetteK , MollerW , et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Radical Research1999;31(3):171-9. [DOI: 10.1080/10715769900300721]">Reljanovic 1999</a>; <a href="./references#CD012967-bbs2-0002" title="ZieglerD , HanefeldM , RuhnauKJ , HascheH , LobischM , SchütteK , et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care1999;22(8):1296-301. [DOI: 10.2337/diacare.22.8.1296]">Ziegler 1999</a>). In <a href="./references#CD012967-bbs2-0001" title="ReljanovicM , ReichelG , RettK , LobischM , SchuetteK , MollerW , et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Radical Research1999;31(3):171-9. [DOI: 10.1080/10715769900300721]">Reljanovic 1999</a>, participants in the two ALA groups (600 mg/day and 1200 mg/day) received intravenous ALA for five days and then oral ALA for 24 months. The three arms in <a href="./references#CD012967-bbs2-0002" title="ZieglerD , HanefeldM , RuhnauKJ , HascheH , LobischM , SchütteK , et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care1999;22(8):1296-301. [DOI: 10.2337/diacare.22.8.1296]">Ziegler 1999</a> were intravenous ALA 600 mg/day for three weeks followed by oral ALA 1800 mg/day for six months, intravenous ALA 600 mg/day for three weeks followed by oral placebo for six months, and intravenous placebo for three weeks followed by oral placebo for six months. We did not consider data from the second arm because the treatment with ALA lasted less than six months. In <a href="./references#CD012967-bbs2-0003" title="ZieglerD , LowPA , LitchyWJ , BoultonAJ , VinikAI , FreemanR , et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care2011;34(9):2054-60. [DOI: 10.2337/dc11-0503]">Ziegler 2011</a>, participants were randomised to oral ALA 600 mg/day or oral placebo for four years. </p> <p>From the three studies, we analysed a total of 816 adults who received either ALA or placebo for at least six months. Two studies included people with type 1 or type 2 diabetes (<a href="./references#CD012967-bbs2-0001" title="ReljanovicM , ReichelG , RettK , LobischM , SchuetteK , MollerW , et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Radical Research1999;31(3):171-9. [DOI: 10.1080/10715769900300721]">Reljanovic 1999</a>; <a href="./references#CD012967-bbs2-0003" title="ZieglerD , LowPA , LitchyWJ , BoultonAJ , VinikAI , FreemanR , et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care2011;34(9):2054-60. [DOI: 10.2337/dc11-0503]">Ziegler 2011</a>), while one study included only people with type 2 diabetes (<a href="./references#CD012967-bbs2-0002" title="ZieglerD , HanefeldM , RuhnauKJ , HascheH , LobischM , SchütteK , et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care1999;22(8):1296-301. [DOI: 10.2337/diacare.22.8.1296]">Ziegler 1999</a>). All trial participants had symptomatic DPN as determined by clinical and electrophysiological examinations. </p> <p>The age range at trial inclusion was 18 to 60 years in <a href="./references#CD012967-bbs2-0001" title="ReljanovicM , ReichelG , RettK , LobischM , SchuetteK , MollerW , et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Radical Research1999;31(3):171-9. [DOI: 10.1080/10715769900300721]">Reljanovic 1999</a>, 18 to 65 years in <a href="./references#CD012967-bbs2-0002" title="ZieglerD , HanefeldM , RuhnauKJ , HascheH , LobischM , SchütteK , et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care1999;22(8):1296-301. [DOI: 10.2337/diacare.22.8.1296]">Ziegler 1999</a>, and 18 to 64 years in <a href="./references#CD012967-bbs2-0003" title="ZieglerD , LowPA , LitchyWJ , BoultonAJ , VinikAI , FreemanR , et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care2011;34(9):2054-60. [DOI: 10.2337/dc11-0503]">Ziegler 2011</a>. The participants' mean age was 57.8 (SD 9.7) years in <a href="./references#CD012967-bbs2-0001" title="ReljanovicM , ReichelG , RettK , LobischM , SchuetteK , MollerW , et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Radical Research1999;31(3):171-9. [DOI: 10.1080/10715769900300721]">Reljanovic 1999</a>, 56.9 (SD 6.3) years in <a href="./references#CD012967-bbs2-0002" title="ZieglerD , HanefeldM , RuhnauKJ , HascheH , LobischM , SchütteK , et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care1999;22(8):1296-301. [DOI: 10.2337/diacare.22.8.1296]">Ziegler 1999</a>, and 53.6 (SD 7.9 years) in <a href="./references#CD012967-bbs2-0003" title="ZieglerD , LowPA , LitchyWJ , BoultonAJ , VinikAI , FreemanR , et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care2011;34(9):2054-60. [DOI: 10.2337/dc11-0503]">Ziegler 2011</a>. </p> <p><a href="./references#CD012967-bbs2-0001" title="ReljanovicM , ReichelG , RettK , LobischM , SchuetteK , MollerW , et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Radical Research1999;31(3):171-9. [DOI: 10.1080/10715769900300721]">Reljanovic 1999</a> had mostly female participants (56.9%), <a href="./references#CD012967-bbs2-0003" title="ZieglerD , LowPA , LitchyWJ , BoultonAJ , VinikAI , FreemanR , et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care2011;34(9):2054-60. [DOI: 10.2337/dc11-0503]">Ziegler 2011</a> had mostly male participants (66.5%), and the distribution of the sexes was equal in <a href="./references#CD012967-bbs2-0002" title="ZieglerD , HanefeldM , RuhnauKJ , HascheH , LobischM , SchütteK , et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care1999;22(8):1296-301. [DOI: 10.2337/diacare.22.8.1296]">Ziegler 1999</a>. </p> <p>Two studies assessed change in symptoms, both using the TSS (<a href="./references#CD012967-bbs2-0002" title="ZieglerD , HanefeldM , RuhnauKJ , HascheH , LobischM , SchütteK , et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care1999;22(8):1296-301. [DOI: 10.2337/diacare.22.8.1296]">Ziegler 1999</a>; <a href="./references#CD012967-bbs2-0003" title="ZieglerD , LowPA , LitchyWJ , BoultonAJ , VinikAI , FreemanR , et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care2011;34(9):2054-60. [DOI: 10.2337/dc11-0503]">Ziegler 2011</a>). The TSS scale ranges from 0 to 14.64 points, with higher scores indicating worse symptoms. The minimal clinically important difference (MCID) is 0.97 points (<a href="./references#CD012967-bbs2-0011" title="Bastyr EJ 3rd, PriceKL , BrilV , MBBQ Study Group. Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy. Clinical Therapeutics2005;27(8):1278-94.">Bastyr 2005</a>). </p> <p>All studies assessed change in impairment. <a href="./references#CD012967-bbs2-0002" title="ZieglerD , HanefeldM , RuhnauKJ , HascheH , LobischM , SchütteK , et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care1999;22(8):1296-301. [DOI: 10.2337/diacare.22.8.1296]">Ziegler 1999</a> and <a href="./references#CD012967-bbs2-0003" title="ZieglerD , LowPA , LitchyWJ , BoultonAJ , VinikAI , FreemanR , et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care2011;34(9):2054-60. [DOI: 10.2337/dc11-0503]">Ziegler 2011</a> used the NIS and the Lower Limbs subscale of the NIS (NIS‐LL), while <a href="./references#CD012967-bbs2-0001" title="ReljanovicM , ReichelG , RettK , LobischM , SchuetteK , MollerW , et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Radical Research1999;31(3):171-9. [DOI: 10.1080/10715769900300721]">Reljanovic 1999</a> used the NDS, developed by Young and colleagues (<a href="./references#CD012967-bbs2-0070" title="YoungMJ , BoultonAJ , MacLeodAF , WilliamsDR , SonksenPH . A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia1993;36(2):150-4.">Young 1993</a>). We decided to analyse the NIS‐LL data from <a href="./references#CD012967-bbs2-0002" title="ZieglerD , HanefeldM , RuhnauKJ , HascheH , LobischM , SchütteK , et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care1999;22(8):1296-301. [DOI: 10.2337/diacare.22.8.1296]">Ziegler 1999</a> and <a href="./references#CD012967-bbs2-0003" title="ZieglerD , LowPA , LitchyWJ , BoultonAJ , VinikAI , FreemanR , et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care2011;34(9):2054-60. [DOI: 10.2337/dc11-0503]">Ziegler 2011</a>, for three reasons. First, DPN predominantly impacts the lower limbs. Second, we combined data from <a href="./references#CD012967-bbs2-0003" title="ZieglerD , LowPA , LitchyWJ , BoultonAJ , VinikAI , FreemanR , et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care2011;34(9):2054-60. [DOI: 10.2337/dc11-0503]">Ziegler 2011</a> (which used the NIS/NIS‐LL) and <a href="./references#CD012967-bbs2-0001" title="ReljanovicM , ReichelG , RettK , LobischM , SchuetteK , MollerW , et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Radical Research1999;31(3):171-9. [DOI: 10.1080/10715769900300721]">Reljanovic 1999</a> (which used the NDS) in <a href="./references#CD012967-fig-0006" title="">Analysis 1.4</a>, and since the NDS focusses on the lower limbs, it is more similar to the NIS‐LL than to the NIS. Third, the intervention effects were similar for the NIS and the NIS‐LL, suggesting these scales may be interchangeable in this context. The NIS‐LL scale ranges from 0 to 88 points, with higher scores indicating more significant impairment; the MCID is considered to be 2 points (<a href="./references#CD012967-bbs2-0024" title="DyckPJ , KratzKM , LehmanKA , KarnesJL , Melton LJ 3rd, O'BrienPC , et al. The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests. Neurology1991;41(6):799-807.">Dyck 1991</a>; <a href="./references#CD012967-bbs2-0048" title="Peripheral Nerve Society. Diabetic polyneuropathy clinical trials: consensus in controlled report of the peripheral nerve society. Annals of Neurology1995;38(3):478-82.">Peripheral Nerve Society 1995</a>). The NDS ranges from 0 to 10 points, with higher scores representing worse impairment. In the analysis that combined different scales, we calculated the SMD. By distribution‐based statistical methods, the MCID is universally equivalent to 0.5 × SD (<a href="./references#CD012967-bbs2-0046" title="NormanGR , SloanJA , WyrwichKW . Interpretation of changes in health‐related quality of life: the remarkable universality of half a standard deviation. Medical Care2003;41(5):582-92.">Norman 2003</a>), which implies that 0.5 is the MCID of outcomes expressed as SMDs. </p> <p>All three studies assessed adverse events.</p> <p>In addition, the included studies measured nerve conduction velocities, nerve or compound muscle action potentials, the Neuropathy Symptoms and Change score, the cooling detection threshold, or the heat pain response slope. </p> <p>Two studies reported glycosylated haemoglobin levels (<a href="./references#CD012967-bbs2-0001" title="ReljanovicM , ReichelG , RettK , LobischM , SchuetteK , MollerW , et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Radical Research1999;31(3):171-9. [DOI: 10.1080/10715769900300721]">Reljanovic 1999</a>; <a href="./references#CD012967-bbs2-0002" title="ZieglerD , HanefeldM , RuhnauKJ , HascheH , LobischM , SchütteK , et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care1999;22(8):1296-301. [DOI: 10.2337/diacare.22.8.1296]">Ziegler 1999</a>). </p> <p>The <a href="./references#CD012967-sec-0095" title="">Characteristics of included studies</a> table provides details of all included studies. </p> </section> <section id="CD012967-sec-0047"> <h4 class="title">Excluded studies</h4> <p>We excluded one study during full‐text review because the duration of treatment was shorter than six months (<a href="./references#CD012967-bbs2-0004" title="MedvedevaLA , GnezdilovAV , Zagorul'koOI , SyroveginAV , SamoilovaNV , Slashchuk IuI. Neurometabolic therapy of diabetic neuropathy. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov [i] Vserossiiskoe obshchestvo psikhiatrov2006;203:71-3. ">Medvedeva 2006</a>; see the <a href="./references#CD012967-sec-0096" title="">Characteristics of excluded studies</a> table). </p> </section> <section id="CD012967-sec-0048"> <h4 class="title">Studies awaiting classification</h4> <p><a href="./references#CD012967-bbs2-0005" title="El-NahasMR , El KannishyG , AbdelhafezH , TaherI , El SehrawyA . Oral alpha-lipoic acid adjunctive treatment for symptomatic diabetic peripheral neuropathy: a prospective, double blind, placebo controlled study. 53rd Annual Meeting of the European Association for the Study of Diabetes, 2017, Lisbon. www.easd.org/media-centre/home.html#!resources/oral-alpha-lipoic-acid-adjunctive-treatment-for-symptomatic-diabetic-peripheral-neuropathy-a-prospective-double-blind-placebo-controlled-study (accessed 20 December 2023). El-NahasMR , ElkannishyG , AbdelhafezH , ElkhamisyET , El-SehrawyAA . Oral alpha lipoic acid treatment for symptomatic diabetic peripheral neuropathy: a randomized double-blinded placebo-controlled study. Endocrine, Metabolic and Immune Disorders Drug Targets2020;20(9):1531-4. [DOI: 10.2174/1871530320666200506081407]">El Nahas 2020</a> compared oral ALA 600 mg twice daily with placebo over six months in people with type 2 diabetes. </p> </section> </section> <section id="CD012967-sec-0049"> <h3 class="title">Risk of bias in included studies</h3> <p>The overall risk of bias was high for all three studies because of attrition rates ranging from 25% to 43% (<a href="#CD012967-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD012967-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012967-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012967.pub2/media/CDSR/CD012967/image_n/nCD012967-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD012967-sec-0050"> <h4 class="title">Allocation</h4> <p>All studies were multicentric and used a central computerised randomisation list. Only <a href="./references#CD012967-bbs2-0003" title="ZieglerD , LowPA , LitchyWJ , BoultonAJ , VinikAI , FreemanR , et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care2011;34(9):2054-60. [DOI: 10.2337/dc11-0503]">Ziegler 2011</a> specified that "a randomization list was generated by the biostatistics department of the manufacturer of the study drug, at distance of the centers the study took place", and "the random allocation was balanced using an undisclosed block size of six". Still, using the current tools, we considered all the studies at low risk of bias regarding allocation. </p> </section> <section id="CD012967-sec-0051"> <h4 class="title">Blinding</h4> <p>We assessed the risk of bias related to blinding for each outcome separately. We considered all three studies at low risk of performance bias because they used a placebo, and because the publications indicated that participants and investigators were blinded. The level of detail on randomisation and blinding procedures in these studies is consistent with the standards of that period. </p> <p>We judged all three studies at low risk of detection bias, as all investigators were blinded to treatment allocation. <a href="./references#CD012967-bbs2-0003" title="ZieglerD , LowPA , LitchyWJ , BoultonAJ , VinikAI , FreemanR , et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care2011;34(9):2054-60. [DOI: 10.2337/dc11-0503]">Ziegler 2011</a> clearly stated that assessors were blinded, and procedures were in place to decode the individual blinded treatment if necessary. In <a href="./references#CD012967-bbs2-0002" title="ZieglerD , HanefeldM , RuhnauKJ , HascheH , LobischM , SchütteK , et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care1999;22(8):1296-301. [DOI: 10.2337/diacare.22.8.1296]">Ziegler 1999</a>, specific additives in the placebo made it similar in appearance to the active medication. </p> <p>Although all studies had symptom‐based scores as the primary outcome, they were probably assessed objectively. </p> </section> <section id="CD012967-sec-0052"> <h4 class="title">Incomplete outcome data</h4> <p>We judged all three studies at high risk of attrition bias.</p> <p>In <a href="./references#CD012967-bbs2-0001" title="ReljanovicM , ReichelG , RettK , LobischM , SchuetteK , MollerW , et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Radical Research1999;31(3):171-9. [DOI: 10.1080/10715769900300721]">Reljanovic 1999</a>, although the study initially included 299 participants in an intention‐to‐treat (ITT) analysis as stated in the protocol, a high attrition rate of 43% (130 participants) was allowed. Furthermore, many participants with outlying electrophysiological results were excluded from the analysis, so that only 65 participants' results were presented. </p> <p>In <a href="./references#CD012967-bbs2-0002" title="ZieglerD , HanefeldM , RuhnauKJ , HascheH , LobischM , SchütteK , et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care1999;22(8):1296-301. [DOI: 10.2337/diacare.22.8.1296]">Ziegler 1999</a>, although data were presented for the primary outcome (change in TSS) at seven months in an ITT analysis for 503/516 randomised participants, the study authors mentioned a 25% withdrawal rate across all groups and provided no explanation regarding the handling of missing data. Additionally, for the secondary outcomes, data were analysed for only a subset of participants (364 for NIS and 368 for NIS‐LL) without any explanation. </p> <p>In <a href="./references#CD012967-bbs2-0003" title="ZieglerD , LowPA , LitchyWJ , BoultonAJ , VinikAI , FreemanR , et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care2011;34(9):2054-60. [DOI: 10.2337/dc11-0503]">Ziegler 2011</a>, while only 6/460 randomised participants were excluded from the analysis, there were high discontinuation rates of 41% in the treatment arm and 42% in the placebo arm over the four‐year study period. The publication did not mention how many outcome measurements were based on the last observation carried forward (LOCF) method ("mean of weeks 191 and 192 or last available value after randomization"). Even in the best‐case scenario of conducting an ITT analysis with complete outcome data, the high attrition rates would have likely diluted the potential benefits of ALA, resulting in insufficient statistical power to detect any effect. </p> </section> <section id="CD012967-sec-0053"> <h4 class="title">Selective reporting</h4> <p>We judged all three studies at low risk of reporting bias.</p> <p><a href="./references#CD012967-bbs2-0001" title="ReljanovicM , ReichelG , RettK , LobischM , SchuetteK , MollerW , et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Radical Research1999;31(3):171-9. [DOI: 10.1080/10715769900300721]">Reljanovic 1999</a> aimed to investigate changes in various outcomes related to neuropathy. The publication reported all specified outcomes at the designated time points. <a href="./references#CD012967-bbs2-0002" title="ZieglerD , HanefeldM , RuhnauKJ , HascheH , LobischM , SchütteK , et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care1999;22(8):1296-301. [DOI: 10.2337/diacare.22.8.1296]">Ziegler 1999</a> focused on measuring changes in TSS and NIS at specific time intervals. Results for these outcomes were reported as initially proposed. Although we could not access the protocols for <a href="./references#CD012967-bbs2-0001" title="ReljanovicM , ReichelG , RettK , LobischM , SchuetteK , MollerW , et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Radical Research1999;31(3):171-9. [DOI: 10.1080/10715769900300721]">Reljanovic 1999</a> or <a href="./references#CD012967-bbs2-0002" title="ZieglerD , HanefeldM , RuhnauKJ , HascheH , LobischM , SchütteK , et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care1999;22(8):1296-301. [DOI: 10.2337/diacare.22.8.1296]">Ziegler 1999</a>, the reported outcomes in these studies align with those typically examined in DPN treatment studies. </p> <p><a href="./references#CD012967-bbs2-0003" title="ZieglerD , LowPA , LitchyWJ , BoultonAJ , VinikAI , FreemanR , et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care2011;34(9):2054-60. [DOI: 10.2337/dc11-0503]">Ziegler 2011</a> had a registered study protocol and reported the results of all prespecified outcomes at both the two‐ and four‐year time points. The publication reported some additional outcomes that were not prespecified in the study protocol, but none were included in our review. </p> </section> <section id="CD012967-sec-0054"> <h4 class="title">Other potential sources of bias</h4> <p>We found no other sources of bias for any study. Pharmaceutical companies sponsored all studies, but we did not consider this a source of bias. All studies were multicentric and had multiple investigators. </p> </section> </section> <section id="CD012967-sec-0055"> <h3 class="title" id="CD012967-sec-0055">Effects of interventions</h3> <p>See: <a href="./full#CD012967-tbl-0001"><b>Summary of findings 1</b> Alpha‐lipoic acid compared to placebo for diabetic peripheral neuropathy</a> </p> <section id="CD012967-sec-0056"> <h4 class="title">Alpha‐lipoic acid versus placebo</h4> <section id="CD012967-sec-0057"> <h5 class="title">Primary outcome</h5> <section id="CD012967-sec-0058"> <h6 class="title">Change in neuropathy symptoms at six months</h6> <p>Only <a href="./references#CD012967-bbs2-0002" title="ZieglerD , HanefeldM , RuhnauKJ , HascheH , LobischM , SchütteK , et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care1999;22(8):1296-301. [DOI: 10.2337/diacare.22.8.1296]">Ziegler 1999</a> reported change in neuropathy symptoms at six months. ALA compared with placebo probably has little or no effect on neuropathy symptoms as assessed by TSS at six months (MD −0.16 points, 95% CI −0.83 to 0.51; 330 participants; moderate‐certainty evidence; <a href="./references#CD012967-fig-0003" title="">Analysis 1.1</a>). The 95% CI was narrow and did not contain the MCID. We downgraded the certainty of the evidence by one level for attrition bias. </p> </section> </section> <section id="CD012967-sec-0059"> <h5 class="title">Secondary outcomes</h5> <section id="CD012967-sec-0060"> <h6 class="title">Change in neuropathy symptoms at six to 12 months and 12 to 24 months</h6> <p>Only <a href="./references#CD012967-bbs2-0003" title="ZieglerD , LowPA , LitchyWJ , BoultonAJ , VinikAI , FreemanR , et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care2011;34(9):2054-60. [DOI: 10.2337/dc11-0503]">Ziegler 2011</a> reported change in neuropathy symptoms beyond six months (at 24 months). ALA compared with placebo probably has little or no effect on neuropathy symptoms as assessed by TSS at 24 months (MD −0.23 points, 95% CI −0.67 to 0.21; 421 participants; moderate‐certainty evidence; <a href="./references#CD012967-fig-0004" title="">Analysis 1.2</a>). The 95% CI was narrow and did not contain the MCID. We downgraded the certainty of the evidence by one level for attrition bias. </p> </section> <section id="CD012967-sec-0061"> <h6 class="title">Change in impairment at six months, six to 12 months, and 12 to 24 months</h6> <p>One study assessed impairment at six months using the NIS‐LL (<a href="./references#CD012967-bbs2-0002" title="ZieglerD , HanefeldM , RuhnauKJ , HascheH , LobischM , SchütteK , et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care1999;22(8):1296-301. [DOI: 10.2337/diacare.22.8.1296]">Ziegler 1999</a>). Two studies assessed impairment at 24 months; <a href="./references#CD012967-bbs2-0001" title="ReljanovicM , ReichelG , RettK , LobischM , SchuetteK , MollerW , et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Radical Research1999;31(3):171-9. [DOI: 10.1080/10715769900300721]">Reljanovic 1999</a> used the NDS and <a href="./references#CD012967-bbs2-0003" title="ZieglerD , LowPA , LitchyWJ , BoultonAJ , VinikAI , FreemanR , et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care2011;34(9):2054-60. [DOI: 10.2337/dc11-0503]">Ziegler 2011</a> used the NIS‐LL. </p> <p>ALA compared with placebo may have little or no effect on impairment as measured by the NIS‐LL at six months (MD −1.02 points, 95% CI −2.93 to 0.89 points; 1 study, 245 participants; low‐certainty evidence; <a href="./references#CD012967-fig-0005" title="">Analysis 1.3</a>). We downgraded the certainty of the evidence by one level for attrition bias and by one level for imprecision. The lower limit of the 95% CI surpasses the MCID (2 points), so we cannot rule out a beneficial effect. </p> <p>ALA compared with placebo probably has little or no effect on impairment at 24 months (SMD −0.07 SDs, 95% CI −0.24 to 0.11; I<sup>2</sup> = 0%, P = 0.39; 2 studies, 486 participants; moderate‐certainty evidence; <a href="./references#CD012967-fig-0006" title="">Analysis 1.4</a>). We downgraded the certainty of the evidence by one level for attrition bias. The 95% CIs did not include the statistical MCID (0.5), which means the possibility of a clinically significant difference is very low. </p> </section> <section id="CD012967-sec-0062"> <h6 class="title">Change in any validated quality of life total score at six months</h6> <p>No studies reported quality of life.</p> </section> <section id="CD012967-sec-0063"> <h6 class="title">Complications of diabetic peripheral neuropathy</h6> <p>No studies reported complications of DPN.</p> </section> <section id="CD012967-sec-0064"> <h6 class="title">Adverse events</h6> <p>All three studies reported adverse events leading to cessation of treatment. There is probably little or no difference between ALA and placebo in the risk of adverse events leading to cessation of treatment (RR 1.48, 95% CI 0.50 to 4.35; I<sup>2</sup> = 0, P = 0.69; 3 studies, 1090 participants; moderate‐certainty evidence; <a href="./references#CD012967-fig-0007" title="">Analysis 1.5</a>). The number of participants for<a href="./references#CD012967-bbs2-0001" title="ReljanovicM , ReichelG , RettK , LobischM , SchuetteK , MollerW , et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Radical Research1999;31(3):171-9. [DOI: 10.1080/10715769900300721]">Reljanovic 1999</a> should have been the 169 participants who completed the 24 months of follow‐up rather than the 65 analysed for the other outcomes. However, the whole cohort was included in the adverse events analysis. We downgraded the certainty of the evidence by one level for attrition bias. </p> <p>No studies recorded all types of adverse event or serious adverse events.</p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012967-sec-0065" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012967-sec-0065"></div> <section id="CD012967-sec-0066"> <h3 class="title" id="CD012967-sec-0066">Summary of main results</h3> <p>This review included three studies with a total of 1089 participants. From the three studies, we analysed 816 adults who received either ALA or placebo for at least six months. </p> <p>All three studies were prospective, double‐blind, placebo‐controlled RCTs with parallel‐group design. Two studies (395 participants) had a three‐arm protocol, and one study (421 participants) had two arms. The studies used different doses of ALA; the minimum dose was 600 mg once daily. Two studies had an initial intravenous regimen of ALA versus placebo for up to three weeks, followed by an oral regimen of ALA versus placebo for up to 24 months. Two studies included both type 1 and type 2 diabetes, and one study included only type 2 diabetes. </p> <p>ALA 600 mg three times daily compared to placebo probably has little or no effect on neuropathy symptoms after six months, and ALA 600 mg once daily compared to placebo probably has little or no effect on neuropathy symptoms after 24 months. We identified only one study for each time frame. The certainty of the evidence for both outcomes was moderate (downgraded for attrition bias). </p> <p>ALA 600 mg once daily compared to placebo may have little or no effect on impairment after six months; however, the 95% CI was wide and included the MCID of the NIS‐LL. Only one study reported this outcome. The certainty of the evidence was low (downgraded for attrition bias and imprecision). </p> <p>Two studies assessed impairment at 24 months using different scales: the NIS‐LL and the NDS. Neither study found a clinically significant improvement with ALA. The certainty of the evidence was moderate (downgraded for attrition bias). </p> <p>We planned to evaluate the impact of ALA treatment on quality of life and the progression of DPN to foot ulceration, amputation, or both. However, no studies reported these outcomes. </p> <p>All three studies reported adverse events. Data from 1090 participants indicated little or no difference between ALA and placebo in adverse events leading to the cessation of treatment at six months after randomisation. The certainty of the evidence was moderate (downgraded for attrition bias). </p> </section> <section id="CD012967-sec-0067"> <h3 class="title" id="CD012967-sec-0067">Overall completeness and applicability of evidence</h3> <p>We included only three studies assessing the benefits and harms of long‐term treatment (more than six months) of DPN with ALA compared to placebo, because most existing studies have a much shorter treatment time. Although all the studies were randomised and double‐blinded and included people of both sexes with a wide age interval (18 to 65 years) from multiple centres, different outcomes of interest were reported in only one or two studies. </p> <p>We found data for symptom improvement, impairment, and adverse events. We did not assess the impact of ALA treatment on quality of life because no studies used a validated quality of life tool. In addition, no studies reported the occurrence of complications (foot ulceration, amputation, or both). </p> <p>A notable limitation arises from the inconsistent reporting of outcomes across studies, as well as the different time frames the study authors selected for their analysis. This may have reduced the robustness of our conclusions. Only one study reported our primary outcome (change in neuropathy symptoms at six months), while another study reported change in neuropathy symptoms at 24 months. Similarly, one study reported our secondary outcome change in impairment at six months (using the NIS‐LL), while two studies reported change in impairment at 24 months (using the NIS‐LL and NDS). Concerning harm, the studies only provided data for adverse events leading to treatment cessation, but not all types of adverse events or serious adverse events. </p> <p>The doses of ALA varied from 600 mg per day to 1800 mg per day, and the route of administration was either oral or intravenous followed by oral. We were unable to perform any subgroup analyses to determine whether the response to treatment varied according to factors like type of diabetes, duration or severity of the disease, age, or route of administration. </p> </section> <section id="CD012967-sec-0068"> <h3 class="title" id="CD012967-sec-0068">Quality of the evidence</h3> <p>Using the GRADE approach, we rated the certainty of evidence as moderate for the primary outcome (change in symptoms at six months) and for all secondary outcomes except change in impairment at six months, which we rated as low. </p> <p>We downgraded the certainty of evidence for all outcomes because of attrition bias. <a href="./references#CD012967-bbs2-0002" title="ZieglerD , HanefeldM , RuhnauKJ , HascheH , LobischM , SchütteK , et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care1999;22(8):1296-301. [DOI: 10.2337/diacare.22.8.1296]">Ziegler 1999</a> had an attrition rate of 25%. <a href="./references#CD012967-bbs2-0003" title="ZieglerD , LowPA , LitchyWJ , BoultonAJ , VinikAI , FreemanR , et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care2011;34(9):2054-60. [DOI: 10.2337/dc11-0503]">Ziegler 2011</a> mentions an attrition rate of 41% for the treatment group and 42% for the placebo groups during the four‐year study period; the study authors performed an ITT analysis at 24 months, but did not report the discontinuation status at that time. <a href="./references#CD012967-bbs2-0001" title="ReljanovicM , ReichelG , RettK , LobischM , SchuetteK , MollerW , et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Radical Research1999;31(3):171-9. [DOI: 10.1080/10715769900300721]">Reljanovic 1999</a> started with 299 participants but presented results for only 65 participants. </p> <p>We also downgraded the certainty of the evidence for change in impairment because of imprecision, because the CI was very wide and contained the MCID. </p> <p>Overall, we assume that the quality of the included studies limits the robustness of our conclusions. </p> </section> <section id="CD012967-sec-0069"> <h3 class="title" id="CD012967-sec-0069">Potential biases in the review process</h3> <p>This review is the first to cover ALA in diabetic neuropathy for a more extended period (at least six months). The review team is mixed, with three members new to the Cochrane review methodology and two experienced members. We received help with the search strategy from a Cochrane expert. This should, in our opinion, minimise selection risk. </p> <p>We consider that the review questions are clearly stated and should not induce bias in the study selection process. They were predefined in the published Cochrane protocol and presented following the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> and PRISMA. All predefined outcomes from the review protocol are discussed in the review. </p> <p>We selected outcomes that answer patient‐relevant questions following PICO recommendations. We included subjective, patient‐reported outcomes (symptom scores) influencing the quality of life. No studies reported objective outcomes like complications (ulcerations or amputations, or both), and this could lead to potential bias in study synthesis. </p> <p>The selection criteria excluded many trials, mainly because of their duration (a few weeks in most cases). We consider that this selection process induces no bias since outcomes of DPN should focus on the long‐term evolution to be clinically meaningful, and the agreement between the review authors concerning the selection of the studies was high. </p> <p>We identified one study that had identical results to a previous conference paper except for the stated time of development of the study (<a href="./references#CD012967-bbs2-0005" title="El-NahasMR , El KannishyG , AbdelhafezH , TaherI , El SehrawyA . Oral alpha-lipoic acid adjunctive treatment for symptomatic diabetic peripheral neuropathy: a prospective, double blind, placebo controlled study. 53rd Annual Meeting of the European Association for the Study of Diabetes, 2017, Lisbon. www.easd.org/media-centre/home.html#!resources/oral-alpha-lipoic-acid-adjunctive-treatment-for-symptomatic-diabetic-peripheral-neuropathy-a-prospective-double-blind-placebo-controlled-study (accessed 20 December 2023). El-NahasMR , ElkannishyG , AbdelhafezH , ElkhamisyET , El-SehrawyAA . Oral alpha lipoic acid treatment for symptomatic diabetic peripheral neuropathy: a randomized double-blinded placebo-controlled study. Endocrine, Metabolic and Immune Disorders Drug Targets2020;20(9):1531-4. [DOI: 10.2174/1871530320666200506081407]">El Nahas 2020</a>). We contacted the study authors and the publisher for clarification, but the study authors refused to share the study data, so we listed the study as awaiting classification. We felt that this action would not induce any bias. </p> <p>As with all reviews that include few trials, ours could lack sensitivity for events with infrequent occurrence, such as adverse events. </p> </section> <section id="CD012967-sec-0070"> <h3 class="title" id="CD012967-sec-0070">Agreements and disagreements with other studies or reviews</h3> <p>We identified several published systematic reviews reporting the effect of ALA on DPN. </p> <p><a href="./references#CD012967-bbs2-0033" title="HanT , BaiJ , LiuW , HuY . A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy. European Journal of Endocrinology2012;167(4):465-71.">Han 2012</a> conducted a similar meta‐analysis that included studies from Chinese biological medicine alongside CENTRAL, MEDLINE, and Embase. The intervention was intravenous ALA. Their primary outcomes were 'benefit', median motor and sensory conduction velocities, and peroneal nerve sensory and motor conduction velocities. Secondary outcomes included the occurrence of adverse events. Of 138 studies screened, the authors of <a href="./references#CD012967-bbs2-0033" title="HanT , BaiJ , LiuW , HuY . A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy. European Journal of Endocrinology2012;167(4):465-71.">Han 2012</a> retrieved 24 full‐text articles (18 in Chinese and six in English) and included 15 studies (all in Chinese). The intervention in all 15 studies was ALA combined with another treatment (methylcobalamin in eight studies, prostaglandins in four, vitamin B1 in one, cilostazol in one, and gingko leaves injection in one). The duration of the intervention ranged from 14 days to 28 days, with a mean of 21 days. There was significant heterogeneity for each of the outcomes presented. The stated limitations were related to the overall poor methodology of the included trials, most of which did not provide details of the study design, randomisation, or allocation. Although the authors of <a href="./references#CD012967-bbs2-0033" title="HanT , BaiJ , LiuW , HuY . A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy. European Journal of Endocrinology2012;167(4):465-71.">Han 2012</a> stated that rigorous studies are needed, they concluded that short‐term ALA treatment is generally safe and can improve both symptoms and nerve conduction speeds. No studies included in <a href="./references#CD012967-bbs2-0033" title="HanT , BaiJ , LiuW , HuY . A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy. European Journal of Endocrinology2012;167(4):465-71.">Han 2012</a> met our inclusion criteria because of the short duration of the interventions. </p> <p>Another published review evaluated intravenous ALA treatment (minimum three weeks) and included only studies from the German VIATRIS repository (<a href="./references#CD012967-bbs2-0071" title="ZieglerD , NowakH , KemplerP , VarghaP , LowPA . Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabetic Medicine2004;21(2):114-21.">Ziegler 2004</a>). Like <a href="./references#CD012967-bbs2-0033" title="HanT , BaiJ , LiuW , HuY . A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy. European Journal of Endocrinology2012;167(4):465-71.">Han 2012</a>, <a href="./references#CD012967-bbs2-0071" title="ZieglerD , NowakH , KemplerP , VarghaP , LowPA . Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabetic Medicine2004;21(2):114-21.">Ziegler 2004</a> concluded that intravenous ALA is effective for improving symptoms and nerve conduction speeds. </p> <p>We identified only one systematic review published since 2020 that evaluated ALA for DPN (<a href="./references#CD012967-bbs2-0006" title="AbubakerSA , AlonazyAM , AbdulrahmanA . Effect of alpha-lipoic acid in the treatment of diabetic neuropathy: a systematic review. Cureus2022;14(6):e25750.">Abubaker 2022</a>). Secondary outcomes included adverse effects of the interventions. There were no inclusion criteria regarding length of treatment, but the included studies had to evaluate standalone ALA treatment and report pain or symptom scores. Eight studies were included, totalling 1500 participants. Two of the included studies were also in our review (<a href="./references#CD012967-bbs2-0001" title="ReljanovicM , ReichelG , RettK , LobischM , SchuetteK , MollerW , et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Radical Research1999;31(3):171-9. [DOI: 10.1080/10715769900300721]">Reljanovic 1999</a>; <a href="./references#CD012967-bbs2-0002" title="ZieglerD , HanefeldM , RuhnauKJ , HascheH , LobischM , SchütteK , et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care1999;22(8):1296-301. [DOI: 10.2337/diacare.22.8.1296]">Ziegler 1999</a>), and one was the study we listed as awaiting classification (<a href="./references#CD012967-bbs2-0005" title="El-NahasMR , El KannishyG , AbdelhafezH , TaherI , El SehrawyA . Oral alpha-lipoic acid adjunctive treatment for symptomatic diabetic peripheral neuropathy: a prospective, double blind, placebo controlled study. 53rd Annual Meeting of the European Association for the Study of Diabetes, 2017, Lisbon. www.easd.org/media-centre/home.html#!resources/oral-alpha-lipoic-acid-adjunctive-treatment-for-symptomatic-diabetic-peripheral-neuropathy-a-prospective-double-blind-placebo-controlled-study (accessed 20 December 2023). El-NahasMR , ElkannishyG , AbdelhafezH , ElkhamisyET , El-SehrawyAA . Oral alpha lipoic acid treatment for symptomatic diabetic peripheral neuropathy: a randomized double-blinded placebo-controlled study. Endocrine, Metabolic and Immune Disorders Drug Targets2020;20(9):1531-4. [DOI: 10.2174/1871530320666200506081407]">El Nahas 2020</a>). Of the four remaining studies, one evaluated ALA in fibromyalgia and not in DPN (<a href="./references#CD012967-bbs2-0032" title="GilronI , RobbS , TuD , HoldenR , TowheedT , ZieglerD , et al. Double-blind, randomized, placebo-controlled crossover trial of alpha-lipoic acid for the treatment of fibromyalgia pain: the IMPALA trial. Pain2021;162(2):561-8.">Gilron 2021</a>). The authors of <a href="./references#CD012967-bbs2-0006" title="AbubakerSA , AlonazyAM , AbdulrahmanA . Effect of alpha-lipoic acid in the treatment of diabetic neuropathy: a systematic review. Cureus2022;14(6):e25750.">Abubaker 2022</a> considered all the studies to be of "high quality", stating as their risk of bias assessment tool the Critical Appraisal Skills Programme (CASP) appraisal tool. They concluded that ALA is safe and tolerable and may reduce symptoms, but that there is limited evidence to support its efficacy. The results of our review also suggest that ALA is safe, but we found no convincing evidence of a beneficial effect. In addition, we considered the studies included in our review to be at high overall risk of bias. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012967-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/media/CDSR/CD012967/urn:x-wiley:14651858:media:CD012967:CD012967-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012967-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012967.pub2/media/CDSR/CD012967/image_n/nCD012967-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/media/CDSR/CD012967/image_t/tCD012967-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/full#CD012967-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/media/CDSR/CD012967/image_n/nCD012967-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012967-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/media/CDSR/CD012967/urn:x-wiley:14651858:media:CD012967:CD012967-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012967-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012967.pub2/media/CDSR/CD012967/image_n/nCD012967-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/media/CDSR/CD012967/image_t/tCD012967-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/full#CD012967-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/media/CDSR/CD012967/image_n/nCD012967-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012967-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/media/CDSR/CD012967/urn:x-wiley:14651858:media:CD012967:CD012967-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Alpha‐lipoic acid (ALA) versus placebo, Outcome 1: Change in validated symptom score at 6 months" data-id="CD012967-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012967.pub2/media/CDSR/CD012967/image_n/nCD012967-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/media/CDSR/CD012967/image_t/tCD012967-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Alpha‐lipoic acid (ALA) versus placebo, Outcome 1: Change in validated symptom score at 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/references#CD012967-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/media/CDSR/CD012967/image_n/nCD012967-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012967-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/media/CDSR/CD012967/urn:x-wiley:14651858:media:CD012967:CD012967-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Alpha‐lipoic acid (ALA) versus placebo, Outcome 2: Change in validated symptom score at 24 months" data-id="CD012967-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012967.pub2/media/CDSR/CD012967/image_n/nCD012967-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/media/CDSR/CD012967/image_t/tCD012967-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Alpha‐lipoic acid (ALA) versus placebo, Outcome 2: Change in validated symptom score at 24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/references#CD012967-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/media/CDSR/CD012967/image_n/nCD012967-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012967-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/media/CDSR/CD012967/urn:x-wiley:14651858:media:CD012967:CD012967-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Alpha‐lipoic acid (ALA) versus placebo, Outcome 3: Change in impairment score at 6 months" data-id="CD012967-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012967.pub2/media/CDSR/CD012967/image_n/nCD012967-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/media/CDSR/CD012967/image_t/tCD012967-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Alpha‐lipoic acid (ALA) versus placebo, Outcome 3: Change in impairment score at 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/references#CD012967-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/media/CDSR/CD012967/image_n/nCD012967-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012967-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/media/CDSR/CD012967/urn:x-wiley:14651858:media:CD012967:CD012967-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Alpha‐lipoic acid (ALA) versus placebo, Outcome 4: Change in impairment score at 24 months" data-id="CD012967-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012967.pub2/media/CDSR/CD012967/image_n/nCD012967-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/media/CDSR/CD012967/image_t/tCD012967-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Alpha‐lipoic acid (ALA) versus placebo, Outcome 4: Change in impairment score at 24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/references#CD012967-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/media/CDSR/CD012967/image_n/nCD012967-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012967-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/media/CDSR/CD012967/urn:x-wiley:14651858:media:CD012967:CD012967-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Alpha‐lipoic acid (ALA) versus placebo, Outcome 5: Adverse events leading to cessation of treatment" data-id="CD012967-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012967.pub2/media/CDSR/CD012967/image_n/nCD012967-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/media/CDSR/CD012967/image_t/tCD012967-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Alpha‐lipoic acid (ALA) versus placebo, Outcome 5: Adverse events leading to cessation of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/references#CD012967-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/media/CDSR/CD012967/image_n/nCD012967-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012967-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Alpha‐lipoic acid compared to placebo for diabetic peripheral neuropathy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Alpha‐lipoic acid compared to placebo for diabetic peripheral neuropathy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with DPN<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> ALA<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with ALA</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in neuropathy symptoms</b><br/>Assessed with: TSS (0 to 14.64, lower is better)<br/>Follow‐up: 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>330<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change was 3.78 points lower</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.16 points lower</b><br/>(0.83 lower to 0.51 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA compared to placebo probably has little or no effect on neuropathy symptoms after 6 months. The 95% CI did not contain the MCID of 0.97 points (<a href="./references#CD012967-bbs2-0011" title="Bastyr EJ 3rd, PriceKL , BrilV , MBBQ Study Group. Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy. Clinical Therapeutics2005;27(8):1278-94.">Bastyr 2005</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in impairment</b><br/>Assessed with: NIS‐LL (0 to 88, lower is better)<br/>Follow‐up: 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>245<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change was 3.37 points lower</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 1.02 points lower</b><br/>(2.93 lower to 0.89 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA compared to placebo may have little or no effect on impairment after 6 months. However, the lower 95% CI limit surpasses the MCID of 2 points (<a href="./references#CD012967-bbs2-0024" title="DyckPJ , KratzKM , LehmanKA , KarnesJL , Melton LJ 3rd, O'BrienPC , et al. The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests. Neurology1991;41(6):799-807.">Dyck 1991</a>; <a href="./references#CD012967-bbs2-0048" title="Peripheral Nerve Society. Diabetic polyneuropathy clinical trials: consensus in controlled report of the peripheral nerve society. Annals of Neurology1995;38(3):478-82.">Peripheral Nerve Society 1995</a>), so we cannot rule out a beneficial effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in any validated quality of life score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Complications of DPN</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events leading to cessation of treatment</b><br/>Follow‐up: 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1090<br/>(3 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.48</b><br/>(0.50 to 4.35) </p> </td> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There is probably little or no difference between alpha‐lipoic acid and placebo probably results in little or no difference in adverse events at 6 months. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 more per 1000<br/>(1 fewer to 7 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ALA:</b> alpha‐lipoic acid; <b>CI:</b> confidence interval; <b>DPN:</b> diabetic peripheral neuropathy; <b>MCID</b> : minimal clinically important difference; <b>MD</b> : mean difference; <b>NIS‐LL:</b> Neuropathy Impairment Score‐Lower Limbs <b>RCT</b> : randomised clinical trial; <b>RR:</b> risk ratio; <b>TSS:</b> Total Symptom Score. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once for risk of bias (attrition bias).<br/><sup>b</sup>Downgraded once for risk of bias (attrition bias) and once for imprecision (95% CI contains the MCID).<br/><sup>c</sup>Downgraded once for risk of bias (attrition bias). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Alpha‐lipoic acid compared to placebo for diabetic peripheral neuropathy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/full#CD012967-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012967-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Alpha‐lipoic acid (ALA) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Change in validated symptom score at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Change in validated symptom score at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Change in impairment score at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Change in impairment score at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.24, 0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Adverse events leading to cessation of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1090</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.50, 4.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Alpha‐lipoic acid (ALA) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012967.pub2/references#CD012967-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012967.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012967-note-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012967-note-0011">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012967-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012967-note-0009">Français</a> </li> <li class="section-language"> <a class="" href="hu#CD012967-note-0010">Magyar</a> </li> <li class="section-language"> <a class="" href="id#CD012967-note-0015">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="ko#CD012967-note-0007">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD012967-note-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD012967-note-0016">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD012967-note-0006">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD012967-note-0005">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD012967-note-0013">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012967-note-0012">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012967\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012967\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012967\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012967\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012967\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012967\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012967\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012967\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012967\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012967\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012967\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012967\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012967\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012967\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012967\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012967\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012967\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012967\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZDBB8PHY&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012967.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012967.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012967.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012967.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012967.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714273510"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012967.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714273514"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012967.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d6aaa780ef3cd',t:'MTc0MDcxNDI3NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 